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POLY (ADP) RIBOSE POLYMERASE INHIBITORS FOR THE TREATMENT OF
MALIGNANT PERIPHERAL NERVE SHEATH TUMOR

Christine Michelle Kivlin, BS
Advisory Professor: Keila E. Torres, MD, PhD

Malignant peripheral nerve sheath tumor (MPNST) is a rare subtype of soft tissue sarcoma.
Surgical excision has remained the standard of care for this highly aggressive malignancy for
over a decade. Conventional chemotherapy and radiotherapy have shown limited efficacy in
MPNST; therefore, it is imperative that targeted treatment be identified to improve the outcome
for MPNST patients. Poly (ADP) ribose polymerase (PARP) inhibitors were first reported over
a decade ago to have substantial anti-tumorigenic effects in malignancies with defective DNA
repair, specifically those with BRCA1/2 (breast cancer, early onset 1/2) mutations. Further
evaluation of these inhibitors has shown multiple mechanisms of sensitivity, all of which are
associated with the DNA damage response and DNA repair. While no specific defects in DNA
repair machinery have been reported in MPNST, sensitivity to PARP inhibition may be
predicted by its complex karyotype and inherent genomic instability. We show increased
PARP1 and PARP2 expression in MPNST patient tumor samples and increased PARP activity
in cell lines. We also demonstrate the anti-MPNST effect of the PARP inhibitor AZD2281 in
vitro and in vivo. Specifically, decreased cell proliferation and induction of apoptosis were
observed in MPNST cell lines at AZD2281 doses and time points similar to, or less than, those
used in cells lines with known DNA repair defects. In addition, AZD2281 treatment suppressed
MPNST subcutaneous xenograft growth and lung metastasis progression, and increased
survival times of mice with metastatic disease. Upon investigation of a potential mechanism of
sensitivity, we found decreased efficacy of homologous recombination (HR) and increased
vi

activity of non-homologous end joining (NHEJ) in MPNST cell lines, suggesting a potential
mechanism of sensitivity to PARP inhibition due to increased genomic instability. We also
observed decreased expression of Cockayne syndrome B (CSB), a pivotal member of the
transcription coupled repair (TCR) pathway. Subsequent overexpression of CSB decreased
the sensitivity of a subset of MPNST cell lines to AZD2281 treatment. Our results suggest that
PARP is a valuable anti-MPNST target and that sensitivity could be due to defective DNA repair
pathways. Moreover, AZD2281 should be evaluated for its efficacy as a therapeutic agent for
MPNST patients.
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Chapter 1
Introduction

1.1 Soft tissue sarcoma
Soft tissue sarcoma (STS) is a relatively rare malignancy, accounting for less than 1%
of adult cancers diagnosed in 2015. (1) These tumors can arise in muscle, fat, blood
vessels, and nerves and occur in any area of the body, with the majority arising in the
extremities. (2) There are over 80 distinct histological subtypes of STS which are classified
and named according to their cell of origin. (3) While the incidence of STS is rare with
approximately 12,000 new cases diagnosed in the United States annually, 41% of patients
are expected to succumb to their disease. (1) Overall, the five-year survival rate for STS is
83% for localized disease and substantially decreases with more advanced disease to 16%
for patients with distant spread. (1)
STS can be categorized into two groups based on the type and extent of the molecular
alterations characteristic of histological subtypes. Several STSs, such as Ewing’s sarcoma,
well-differentiated liposarcoma, have a “simple karyotype”, with defined recurring
chromosomal translocations and copy number changes that are linked to tumorigenesis.
(4) Within this category are also those STSs with specific genetic mutations that drive tumor
formation such as the v-kit hardy-zuckerman 4 feline sarcoma viral oncogene (cKIT) or
platelet-derived growth factor receptor, beta polypeptide (PDGFRB) mutation in
gastrointestinal stromal tumor. (5) However, the majority of STSs has complex karyotypes
associated with substantial chromosomal aberrations and high levels of genomic instability.
(6) One example of a karyotypically complex STS is malignant peripheral nerve sheath
tumor (MPNST).
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1.2

Malignant peripheral nerve sheath tumor

Incidence and clinical features
MPNST accounts for 2-5% of all STS diagnoses, accounting for approximately 238
new cases in the United States annually (Figure 1). (3,7) MPNST can arise in three settings:
sporadic, neurofibromatosis type 1-associated (NF1-associated), and radiation-associated.
Sporadic MPNST accounts for 40% of cases, while NF1-associated MPNST accounts for
50% of cases. Radiation-associated MPNST occurs in a field of prior therapeutic radiation
and accounts for 10% of cases. (7-9)

Figure 1. Soft tissue sarcoma subtypes. Distribution by histology for adult patients with
soft tissue sarcoma, all sites. MSKCC 7/1/1982-6/30/2010. GIST: gastrointestinal stromal
tumor; UPS: undifferentiated pleomorphic sarcoma; MPNST: malignant peripheral nerve
sheath tumor
Reprinted with permission from Springer New York (3), copyright 2013.
2

In general, MPNST is a highly aggressive tumor that often occurs in the upper or lower
extremities involving large nerve bundles such as the sciatic nerve or the brachial plexus.
(7) Due to the rapidly growing nature of the disease, patients will present with pain, motor
weakness, or paresthesia; additionally, up to 50% of patients will present with systemic
disease. (7)
Neurofibromatosis type 1-associated malignant peripheral nerve sheath tumor
Neurofibromatosis type 1 (NF1) is the most common hereditary disease affecting
approximately 1 in 3000 individuals. NF1 is typified by several clinical features, most
commonly café-au-lait spots, skinfold freckling, cognitive impairment, and cutaneous
neurofibromas (Figure 2). (10) In NF1 patients, a mutation of one allele of the neurofibromin
1 (NF1) gene is inherited in an autosomal dominant fashion, or occurs de novo, and is
defective in all cells, resulting in a loss of heterozygosity. A second acquired mutation then
occurs in Schwann cells resulting in the formation of neurofibromas. According to the
human gene mutation database, almost 1500 mutations of NF1 have been reported and
are associated with the disease phenotype. Approximately 5-10% of NF1 patients will have
a large deletion of NF1 accompanied by a deletion in the surrounding chromosomal area,
which is associated with a severe phenotype; or microdeletions either 1.4Mb in size
encompassing 14 genes or 1.3Mb in size encompassing 13 genes. (11) However, the
majority of patients (approximately 90%) will have a NF1 intragenic mutation, where no
clear phenotype-genotype correlation has been established. (11,12)

3

Figure 2. Clinical manifestations of neurofibromatosis type I (NF1).
Reprinted with permission from the neurofibromatosis network.
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Neurofibromas manifest as superficial cutaneous neurofibromas (localized nodules
on or beneath the skin found in almost all adult NF1 patients) and/or as diffuse or plexiform
neurofibromas (deep-seated tumors that growth along the length of large nerve bundles
which occur in approximately 30-40% of patients). (13) Only deep neurofibromas can
undergo malignant transformation to become MPNSTs, which is the main cause of
morbidity and mortality of NF1 patients. (14) Malignant transformation in NF1 patients
peaks at adolescence with an increased risk remaining through adulthood. (15) There is an
estimated 8–13% lifetime risk of MPNST development in NF1 patients (Figure 3). (13)

Figure 3. Neurofibromatosis type I molecular pathogenesis. Neurofibromatosis 1 (NF1)
is a neurogenetic disorder caused by loss of function of the NF1 gene. Neurofibromas are
the most common benign peripheral nerve sheath lesions in NF1 and manifest as superficial
5

cutaneous neurofibromas (nonplexiform) in virtually all patients and/or as deep (often
plexiform) neurofibromas. Only deep neurofibromas have the significant propensity to
undergo malignant transformation to MPNSTs, with an estimated 8–13% lifetime risk in a
patient. Most MPNSTs are believed to arise in association with deep neurofibromas, but
they may arise outside of this context as well. In the superficial cutaneous neurofibroma
panel, a clinical photograph depicts a cutaneous neurofibroma (red arrow), and a
radiograph from a different patient shows both superficial (red arrow) and deep (blue arrow)
neurofibromas involving the lower extremity. The haematoxylin and eosin (H&E)
photomicrograph shows a dermal neurofibroma. The deep neurofibroma panel features a
radiograph of lobular, plexiform neurofibroma (red arrow) deep in the pelvis and an H&E
image of a plexiform neurofibroma associated with a nerve (blue arrow). Additional
molecular events must accumulate for malignant transformation. In the MPNST panel, an
intraoperative photograph shows an MPNST in an NF1 patient involving the sciatic nerve
with a histological photomicrograph of an MPNST below. The images to the right show a
radiograph of an MPNST near the scapula and a PET (positron emission tomography)
image showing avid glucose uptake consistent with intense metabolic activity in the same
case directly below. Clinical and radiographic images were kindly provided by John
Madewell, John Slopis and Ian McCutcheon of M.D. Anderson Cancer Center, Houston,
TX, USA. Abbreviations: LOH, loss of heterozygosity; MPNST, malignant peripheral nerve
sheath tumour; NF1, neurofibromin gene.
Reprinted with permission from Cambridge University Press: [Expert Reviews in Molecular
Medicine] (13), copyright 2009.
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Molecular characteristics
The NF1 gene encodes the protein neurofibromin which functions as a Ras GTPaseactivating protein, a key negative regulator of the mitogen-activated protein kinase (MAPK)
pathway. Mutated NF1 effects the expression and/or function of neurofibromin. Loss of
neurofibromin function results in dysregulated Ras activity and hyperactive MAPK signaling,
leading to constitutive activation of downstream pathways and increased cell proliferation.
(10) Association with a genetic cancer predisposition disorder makes MPNST unique from
other STS subtypes.
Available treatment options
MPNST is largely unresponsive to chemotherapy or radiotherapy; however,
neoadjuvant chemotherapy has been shown to provide disease stabilization, and external
beam radiation therapy may offer improved local control. (16) Therefore, the mainstay of
treatment for MPNST is surgical resection, though this is often difficult due to the location
and size of these tumors. (17,18) Recent studies have identified several recurring genetics
aberrations in MPNST (occurring in NF1, TP53, CDKN1B, PDGFRA, HGF, and others), as
well as irregular receptor tyrosine kinase activity that could be exploited for treatment or
highlight other targetable molecular dysregulations. (19-21) However, clinical trials
evaluating targeted agents such as erlotinib (targeting EGFR), sorafenib (targeting VEGF
and RAS), and imatinib (targeting KIT) reported minimal observed responses in STS
patients, including those with MPNST. (7,22)
Patient outcome
Even with surgical resection of primary disease, studies show MPNSTs have a high
propensity to recur (40%-65%) and metastasize (41%). (13,23) Metastasis typically occurs
to the lung (67%) with the liver and brain being less common sites (36%). (23) Additionally,
in the MD Anderson Cancer Center experience with MPNST cases, the five-year survival
7

rate for patients with NF1-associated MPNST is approximately 48%. The five-year survival
rate decreases substantially in patients with radiation-associated MPNST (43%), while
increasing slightly in patients with sporadic MPNST (63%) (Figure 4). (24)

Figure 4. Disease-specific survival of MPNST patients by etiology.
Reprinted from Watson, K. L., Al Sannaa, G. A., Kivlin, C. M., Ingram, D. R., Landers, S.
M., Roland, C. L., Cormier, J. N., Hunt, K. K., Feig, B. W., Guadagnolo, B. A., Bishop, A.
J., Wang, W.-L., Slopis, J. M., McCutcheon, I. E., Lazar, A. J. & Torres, K. E. Patterns of
recurrence and survival in sporadic, neurofibromatosis type 1-associated, and radiationassociated malignant peripheral nerve sheath tumors (MPNSTs). Journal of Neurosurgery,
In Press. (2016). (24)
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1.3 Poly (ADP) ribose polymerases
Family members and function in DNA repair
Poly (ADP) ribose polymerases (PARP) were first identified in 1966 with the discovery
of PARP1. (25) Subsequent PARPs were characterized based on their sequence homology
to the PARP domain/catalytic domain in PARP1, resulting in a PARP superfamily with 17
members, named sequentially PARP1- PARP 16. (26) PARPs contain several conserved
domains: domain A is a deoxyribonucleic acid (DNA) binding domain containing two zinc
fingers, domain B contains a nuclear localization sequence, domain D is an
automodification domain, and domain F is the catalytic domain. (27,28) The enzymatic
product of PARP is poly (ADP) ribose (PAR) which acts to post-translationally modify
nuclear acceptor proteins. (28) Enzymatic activity has mainly been attributed to PARP1
(>90%) and PARP2 (5-10%). (25,29)
Upon stimulation by DNA single strand breaks, PARP catalytic activity increases
approximately 500 fold and, via its DNA binding domain, binds to sites of DNA damage. (25)
Using the ADP ribosyl moiety of NAD as a substrate, PARP generates long, often branched,
chains of PAR of various sizes in successive transfer cycles onto nuclear acceptor proteins
with the release of nicotinamide. (28) Poly (ADP) ribosylation (PARylation) domains
frequently overlap with the functional domains of acceptor proteins, thereby altering their
function. (30) Additionally, PAR is highly negatively charged, therefore PAR can also alter its
acceptor protein’s functions, including protein-protein interactions, protein-nucleic acid
interactions, enzymatic activity, and/or subcellular localization, via charge effects or by acting
as a steric block due to its large size. (31) This is a well-balanced process which leads to a
rapid turnover of PAR. Poly (ADP) ribose glycohydrolase (PARG) splits the ribose-ribose
linkages of PAR, creating free ADP-ribose and de-PARylating the acceptor protein (Figure 5).
(28)
9

Figure 5. Poly (ADP) ribose polymerase function. Poly (ADP- ribose) polymerases
(PARPs) use the ADP-ribosyl moiety (L- shaped symbols in blue) for NAD+ to covalently
modify acceptor proteins in successive transfer cycles thus creating branched chains of poly
(ADP-ribose), with stoichiometric release of nicotinamide. Poly (ADP-ribose) glycohydrolase
(PARG) splits the ribose- ribose linkages between ADP- ribosyl units of the polymer, thus
creating free ADP- ribose.
Modified and reprinted with permission from John Wiley and Sons: [Bioessays] (28),
Copyright 2001.
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The classic role of PARP is in DNA damage repair through the base excision repair
(BER) pathway. Upon single strand DNA damage, PARP signals the extent of injury and
relaxes the chromatin, by PARylating histones, for increased access to DNA breaks;
additionally, a large portion of PAR is bound to PARP itself in an automodification reaction.
PARP activity recruits other repair proteins either directly by PARylation or indirectly
through interaction with other PARylated proteins, such as the scaffold protein x-ray repair
complementing defective repair in Chinese hamster cells 1 (XRCC1), that assemble and
activate BER. PARylation of PARP1 causes its release from damaged DNA which
suppresses further PAR synthesis and provides access for other repair proteins to fully
repair the DNA insult (Figure 6). (32,33) The BER process begins with the recognition and
removal of the damaged base by DNA glycosylase, which creates an abasic site (AP site).
(34) The DNA backbone is then cut on the 5’ side by an AP endonuclease, such as apurinicapyrimidinic endonuclease 1 (APEX1), which is subsequently removed by a DNA
phosphodiesterase. DNA polymerase 1 then replaces the missing base alone (short patch
BER) or along with several bases downstream by first removing them with its 5’ to 3’
exonuclease activity, then replacing them with its polymerase activity (long patch BER).
(35-37) Long patch BER also requires the activities of PCNA to assist DNA polymerase in
displacement and synthesis of DNA longer than one base. (37) This process creates a flap
that is incompatible with ligation. (37) Therefore, flap endonuclease 1 cleaves the resulting
flap so the gaps can be ligated. (37) DNA ligase 3 (short patch BER) or DNA ligase 1 (long
patch BER) completes the repair by annealing the gap. (34,36) PARP1 has been shown to
be able to bind to approximately 90% of genes transcribed by RNA polymerase II;
additionally PARP2 is a positive cofactor for transcription of approximately 600-1000 genes.
(33) PARylation acceptor proteins also include those involved in transcription, replication,
cell cycle, chromatin structure, and cell death, therefore PARPs have non-DNA damage
function as well. (38)
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Figure 6. Effect of Poly (ADP) Ribose Polymerase function and inhibition on DNA
repair. PARP is activated in response to DNA SSB by detecting and binding SSB to initiate
the process of BER. Its catalytic activity results in poly(ADP-ribosyl)ation on itself and other
key BER proteins such as XRCC1. Activated PARP then recruits other DNA repair proteins
via poly(ADP-ribosyl)ation and direct interactions to facilitate DNA repair. The cellular levels
of PAR are regulated by the opposing actions of PARP and PARG. Degradation of PAR
polymer by PARG leads to release of modified proteins from damaged DNA. PARP
inhibition causes an increase in persistent SSBs in DNA that are converted into DSBs. Both
HR and DDR proteins are involved in the repair of DSBs. However, HR deficient cells or
cells with BRCAness are unable to repair the accumulated DSBs caused by PARP
inhibition, resulting in collapsed replication forks, chromosome instability and cell death.
Reprinted from Wang X, Weaver DT. The ups and downs of DNA repair biomarkers for PARP
inhibitor therapies. American Journal of Cancer Research. 2011;1(3):301-327. (32)
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Poly (ADP) ribose polymerase inhibition
Nicotinamide was the first PARP inhibitor to be established and was evaluated almost
thirty years ago. (39) Second generation PARP inhibitors were then discovered through
screening of chemical libraries, thus enhancing the potency and structure-specific activity of
these inhibitors. (40) The current third generation inhibitors act as a competitive inhibitor of
NAD, the substrate of PAR. (41,42)
There are two approaches for the clinical development of PARP inhibitors: (1) exploit a
defect in the targeted cell so the cell dies when PARP activity is lost (synthetic lethality) or (2)
use a PARP inhibitor as a chemosensitizer, in combination with traditional chemotherapy or
radiotherapy. Synthetic lethality is the principle that either of two mutations has no effect, but
the combination of mutations is lethal. This idea was applied to cancer therapeutics in 1997.
(43) For example, the addition of a PARP inhibitor would compromise the efficacy of BER and
lead to the conversion of single strand breaks to double strand breaks. If the cell has intact
DNA double strand break repair machinery, the damage can be repaired and the cell would
survive. However, if PARP inhibition is applied to a cell with a deficiency in homologous
recombination (HR), the error-free pathway of DNA double strand break (DSB) repair, the cell
will be unable to fix the damage and the replication fork will collapse, leading to chromosomal
instability and cell death due to mitotic catastrophe (Figure 6). (32,44)
Most notably, PARP inhibition in tumors with a breast cancer 1/2, early onset (BRCA1/2)
mutation or a BRCA-deficient phenotype without a germline BRCA mutation (termed
“BRCAness”) was shown to cause synthetic lethality. (45,46) The majority of preclinical and
subsequent clinical studies with PARP inhibitors have been performed in BRCA-mutated
breast and ovarian carcinomas with significant anti-tumor effects reported. (47) Over 100
clinical trials have been performed with an array of PARP inhibitors alone and in combination
with conventional chemotherapies.
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The PARP inhibitor AZD2281 (Olarparib) is arguably the most well-characterized PARP
inhibitor clinically available, and has been shown to have significant single-agent efficacy in
BRCA-mutant cells and synergizes with DNA-damaging platinum drugs in preclinical studies.
(48,49) In clinical trials, AZD2281 has been shown to be generally well-tolerated and
produced an objective response in 47% of 19 patients with BRCA-mutant breast, ovarian, or
prostate cancer, in addition to a 63% disease control rate. (50,51) Currently, AZD2281 is in
several phase 3 clinical trials including study of olaparib in ovarian cancer (SOLO1 and
SOLO2) for BRCA-mutated ovarian cancer.
However, recent studies have revealed that due to the nature of BRCA mutations, drugresistant populations can form, due to secondary mutations that restore wildtype function of
BRCA, increased expression and function of hypomorphic BRCA1/2, or increased drug efflux.
(52) Because this population seems to develop over a period of time, a heterogeneous tumor
population may exist prior to treatment. Continued exposure to a PARP inhibitor results in the
selection of the drug resistant population, which becomes the predominate population,
therefore PARP inhibition is no longer an effective therapy. (52)
Almost ten years ago, studies showed that cancer cells with defective DNA repair
proteins such as ataxia telangiectasia and Rad3 related (ATR), ataxia telangiectasia mutated
(ATM), and checkpoint kinase 1/2 (CHK1/2) are profoundly sensitive to PARP inhibitors and
may represent biomarkers for patient selection and PARP efficacy. (46,53) In addition, the
presence of the EWS-FLI1 fusion protein, resulting from the EWS RNA-binding protein 1-Fli1 proto-oncogene, ETS transcription factor translocation in Ewing’s sarcoma, has been
shown to elicit PARP inhibitor sensitivity. (54) This preclinical observation has led to a current
clinical trial for Ewing’s sarcoma patients that have failed traditional chemotherapies. Lord
and Ashworth have also proposed other predictive biomarkers of PARP inhibitor sensitivity
including loss of function mutations of cyclin-dependent kinase 12 (CDK12), often found in
serous ovarian cancer, and loss of expression of excision repair cross-complementation
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group 1 (ERCC1), seen in non-small cell lung cancer. (51) These findings expand the use of
PARP inhibitors beyond BRCA-mutant cancer types and could lead to larger clinical trials
where patients are included based on genetic screenings of their tumors.
1.4 Nucleotide excision repair
Function in DNA repair
The nucleotide excision repair (NER) pathway repairs bulky DNA lesions that cause
a distortion of the DNA; the two major types of photoproducts that result in this type of
distortion are cyclobutane pyrimidine dimers (CPDs) and [6,4]-pyrimidine dimers. (55,56)
This type of DNA adduct can be caused by exogenous (UV) or endogenous (reactive
oxygen species) sources. (57) The pathway is divided into two sub-pathways: repair of the
actively transcribed pathway (transcription coupled repair), and the non-transcribed region
(global genome repair). (58) During transcription coupled repair (TCR), DNA damage is
detected through the arrest of RNA polymerase. (59) Cockayne syndrome A and B then
allow access to the DNA damage site by inducing dissociation of RNA polymerase as well
as recruiting several TCR-specific proteins involved in chromatin remodeling for rapid repair
of the lesion, including UV-stimulated scaffold protein A (UVSSA), ubiquitin-specificprocessing protease 7 (USP7), XPA-binding protein 2 (XAB2), high mobility group
nucleosome-binding domain-containing protein 1 (HMGN1), and the transcriptional
elongation factor, TFIIS. (60,61) These factors help to facilitate chromatin remodeling and
enable the resumption of transcription after the lesion is removed. (62) DNA damage in
global genome repair is detected through the binding of xeroderma pigmentosum,
complementation group C (XPC) (further stabilized by human homolog of RAD23B
(HHRAD23B) and centrin 2 (CETN2)), and XPE which serves to further stimulate XPC
binding to the lesion, and is thought to further distort the DNA structure. (61) Subsequent
steps of DNA repair are identical between the two sub- pathways. (63) The general
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transcription factor complex (TFIIH) binds the area of DNA damage through the interaction
with either XPC or the arrested transcription machinery. (63) This complex is composed of
ten subunits, most notably xeroderma pigmentosum, complementation group B (XPB) and
xeroderma pigmentosum complementary group D (XPD). XPB and XPD are DNA helicases
which unwind DNA from 5’ to 3’ or 3’ to 5’ respectively, near the damaged base. XPD also
acts as a verification step and checks for distortion of the DNA strand, as well as, a
damaged base to prevent unnecessary NER. (59,63) Once the DNA is unwound, replication
protein A (RPA) is recruited and acts to protect the separated single strand. (60) Xeroderma
pigmentosum, complementation group G (XPG), a structure specific nuclease, is also
recruited at this time, whereas XPC is released, free to recognize other damaged sites to
initiate a new round of NER. (64) The area around the damage is then cleaved by
XPG/XPA, a 3’ nuclease, and a 5’ nuclease, xeroderma pigmentosum, complementation
group F-excision repair cross-complementation group 1 (XPF-ERCC1). (60,65) The region
containing the lesion is displaced, allowing for gap repair synthesis. DNA polymerase delta
(along with replication factor C (RFC), and proliferating cell nuclear antigen (PCNA)), or
DNA polymerase epsilon alone bind to the 3’-OH overhang created by the cut of XPFERCC1 and extend the DNA to span the gap, thus causing the displacement of the repair
proteins. (59,65) The gap is finally ligated by DNA ligase I or by DNA ligase III in non-cycling
cells (Figure 7). (58,61)
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Figure 7. Nucleotide excision repair. The nucleotide excision repair (NER) system
consists of a series of reactions by which DNA damage caused by, for example, ultraviolet
radiation-induced photoproducts or similar chemically induced products is recognized and
repaired. Damage can occur from external and endogenous sources (shown as a balance
in the figure). Photoproducts include cyclobutane pyrimidine dimers (CPDs) and [6–4]
photoproducts, which can both involve T and C pyrimidines. When repair of these photo- or
chemical products is faulty owing to mutations in the NER system, replication errors lead to
characteristic C to T mutations, especially CC to TT mutations, which are found in TP53,
Patched 1 (PTCH1) and other oncogenes in sunlight-induced skin cancers of patients with
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xeroderma- pigmentosum (XP) and others. The damage is endogenous in other systemic
disorders and is thought to be caused mainly by reactive oxygen species (ROS). Depending
on whether the damage occurs in a transcriptionally active or inactive domain, repair can
occur by two pathways: global genomic repair (GGR) or transcription-coupled repair (TCR)
(shown in the figure). Damage in transcriptionally active regions is detected through the
arrest of transcription by RNA polymerase I (RNAPI; not shown) and RNA polymerase II
(RNAPII). Transcription arrest is enhanced by mutations in the Cockayne syndrome A
(CSA) and Cockayne syndrome B (CSB) proteins, and both are required for ubiquitylation
of the carboxy-terminal domain of RNAPII. Cells with mutations in CSA (also known as
ERCC8) and CSB (also known as ERCC6) do not show the increased rate of photoproduct
repair in transcriptionally active regions that occurs in normal cells, and carry out GGR at
normal rates. Arrested polyubiquitylated RNAPII is removed and degraded, leaving the
active genes accessible for repair and the resumption of transcription. CSA is a WD40
protein that is part of the ubiquitin E3 ligase that acts on XPC and DNA damage-binding 2
(DDB2). Damage in transcriptionally inactive regions is detected by the DNA
damage-binding protein XPC and complex Damage-Specific DNA Binding Protein 1 (XPE).
Mutation of either of these can cause XP140. The individual DNA damage-binding proteins
have weak affinities for their substrate, so the binding process can be viewed either as a
sequential process in which one protein facilitates binding by another or as a grouping of
weakly interacting partners that form transient pre-incision complexes that are locked in
place by the XPB (also known as ERCC3) ATPase. The CPDs and [6–4] photoproducts
make substantially different structural changes in DNA: CPDs are much less distorting and
require more active participation of XPE. Damage recognition is followed by binding of the
ten-component basal transcription factor TFIIH through interaction with either XPC or the
arrested transcription apparatus. XPD (also known as ERCC2) is a component of TFIIH
and is a DNA helicase that is involved in 5′ to 3′ unwinding of the DNA in the vicinity of a
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damaged base. ATP hydrolysis by the XPB component of TFIIH facilitates binding of the
NER complex to the damaged site. The amino terminus of XPB interacts with XPD and
XPG (also known as ERCC5), whereas the carboxyl terminus is required for 5′ cleavage.
XPD carries out a further damage recognition step when its migration along the helix is
blocked by a photoproduct. The DNA around the damaged site is then cleaved by the XPG
3′ nuclease and the XPF–ERCC1 5′ nuclease. Recent evidence suggests that 5′ cleavage
occurs first. XPG is bound through interaction with XPC and TFIIH. The nucleases are
anchored by XPA–replication protein A (RPA), which defines the cleavage sites and strand
specificity. Once the damaged oligonucleotide is removed, a patch is resynthesized by
proliferating cell nuclear antigen, polymerases δ, ε or κ and a ligase. In quiescent cells,
ligation involves X-ray repair cross-complementing protein 1 (XRCC1) and ligase III. In
proliferating cells, ligation involves ligase I.
Reprinted with permission from Nature Publishing Group: [Nature Reviews Genetics] (66),
copyright 2009.
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Mutations within the NER pathway can give rise to xeroderma pigmentosum (XP),
caused by a mutation in XP (subtype A-G) genes, Cockayne syndrome (CS), caused by a
mutation in ERCC6/8, or trichothiodystrophy, caused by a mutation in ERCC2/3. (65) Cells
with a mutation in CSA or CSB do not show the increased rate of DNA repair in the
transcriptionally active strand due to a loss of TCR, instead those cell carry out GGR at
normal rates. (57,66) CS patients have light sensitivity, neurological, facial, and limb
abnormalities, premature aging, dwarfism, and often early death due to neurodegeneration.
(57,63,66) If the NER pathway is deficient, the replication fork may collapse and the single
strand breaks can be converted into double strand DNA breaks. (67,68)
Possible implication with poly (ADP) ribose polymerase inhibitors
In addition to BRCAness, other components of DNA repair may determine sensitivity to
PARP inhibition. Lord and Ashworth demonstrated, via siRNA screen, that the nucleotide
excision repair genes, XPA binding protein (XAB2) and damage-specific DNA binding protein
(DDB1), were lethal targets when combined with PARP siRNA. (69) The authors
hypothesized that TCR-deficient cells may stall the replication fork in response to DNA
lesions, leading to cell cycle arrest until the fork can be restarted. This can lead to collapse of
the replication fork and double strand DNA breaks beyond a threshold that is compatible with
cell viability. Therefore a TCR deficiency can make cells sensitive to PARP inhibition.
1.5 Double strand DNA repair mechanisms
Homologous Recombination
Double strand DNA breaks are the most detrimental form of DNA damage. (70)
Double strand DNA breaks can occur through multiple physical (ex: replication across a
nick) or pathological (ex: ionizing radiation) means. (71) There are two main methods of
double strand DNA break repair: homologous recombination (HR) and non-homologous
end joining (NHEJ). HR is a high fidelity pathway that requires a homologous region of DNA
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as a template to repair the damage and therefore occurs during S and G2 phases of the
cell cycle. (70,72,73) HR is initiated when the meiotic recombination 11/ RAD50 homolog/
Nijmegen breakage syndrome 1 (MRE11/Rad50/NBS1 [MRN]) complex and CtBP
interacting protein (CtIP) are recruited to sites of double strand DNA damage. (73) This
leads to 5’ to 3’ end resection of the DNA by MRN and further resection by exonuclease 1
(EXO1) to produce long stretches of 3’ single strand DNA, which is then coated by
replication protein A (RPA) to prevent the formation of secondary structure. (58,73,74)
Resection of the DNA ends commits the repair of the DSB to the HR pathway as opposed
to NHEJ and is facilitated by BRCA1. (75,76) BRCA2, in a relatively not-well understood
process, interacts with BRCA1, BRCA1 associated RING domain 1 (BARD1), and partner
and localizer of BRCA2 (PALB2) to displace RPA, and enable the loading of
RAD51 recombinase (Rad51) onto the 3’ overhangs. (58,73,74,77) The Rad51-DNA
filaments, referred to as the nucleofilament, further stabilized by Rad54 then invade the
sister chromatid in search of a homologous sequence and form the synaptic complex, a
three strand intermediate that allows the invading strand to anneal with the complementary
strand and displace the third strand to form a structure known as the D loop. (58,72,74,78)
The 3’ end of the invading strand is then extended by DNA polymerases, in a process called
strand extension. (73) If this newly synthesized strand dissociates from the template strand
and reanneals with the other original ssDNA overhang, it will form a non-crossover product
in a process termed synthesis-dependent strand annealing (SDSA). (72,74) Evidence
suggests this is the main conclusion of DNA DSBs in somatic mammalian cells. (79)
Otherwise the extension of the invading strand can cause the D loop to migrate until it
reaches the second end of the double strand break where it can form two Holliday junctions
(HJs), in a process called second end capture. (72) The bloom syndrome, recQ helicaselike-topoisomerase III-recQ mediated genome instability 1 (BLM-TOPOIII-RMI1) complex
can then resolve the Holliday junctions to a non-crossover product. (58,72,74) Alternatively,
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the Holliday junctions can be ameliorated by HJ resolvases such as MUS81 structurespecific endonuclease subunit- essential meiotic structure-specific endonuclease 1
(MUS81-EME1), GEN1 (Holliday junction 5' flap endonuclease), or SLX1 structure-specific
endonuclease (SLX1-SLX4), which can lead to crossover or non-crossover products due
to their symmetrical cleavage of the Holliday junctions (Figure 8). (58,74)

Figure 8. Homologous Recombination (HR). After DNA damage end resection by MRN
and CtIP, PALB2–BRCA2 activates RAD51 to promote the invasion of an undamaged
template, leading to synthesis-dependent strand annealing or second-end capture and
double–Holliday junction formation to allow DSB repair.
Reprinted with permission from Nature Publishing Group: [Nature Structural and Molecular
Biology] (77), Copyright 2010.
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Implication with PARP inhibitors
PARP inhibitors are primarily used in malignancies with a deficiency in homologous
recombination (HR) in order to enhance the conversion of single strand DNA breaks to
double strand DNA breaks. The inability of the HR deficient cell to efficiently repair double
strand DNA breaks translates into replication fork collapse and cell death. (80) However,
there are currently no publications citing a homologous recombination pathway deficiency
in MPNST.
Non-Homologous End Joining
Determining whether double strand DNA breaks will be repaired by HR or NHEJ is a
complex question. If the damage occurs outside of the S or G2 phase where a sister
chromatid or homologous chromosome is not available, HR cannot occur and NHEJ must
be used to repair the damage. (71,73) In addition, tumor protein p53 binding protein 1
(53BP1) and its effector replication timing regulatory factor 1 (Rif1) act to antagonize
BRCA1 and direct repair through NHEJ. (76) Upon DNA damage, the Ku autoantigen p70
subunit/Ku autoantigen p80 subunit (Ku70/Ku80) heterodimer binds to each side of the
double strand break and prevents non-specific 5’ end resection. (74,81) This protein has a
high affinity for DNA ends and is ubiquitously expressed in the cell (approximately 500,000
molecules per cell); once bound it is referred to as a Ku:DNA complex. (71,74,81) These
end complexes can recruit subsequent nuclease, polymerase, and ligase proteins in any
order, causing a large number of outcomes that can possibly result from the same starting
lesion in NHEJ. (58,82) DNA-dependent protein kinase catalytic subunit (DNA-PKcs) is
recruited to the Ku:DNA complex and forms the DNA-PK holoenzyme. Artemis is recruited,
phosphorylated, and therefore activated by DNA-PKcs, where it processes incompatible
DNA ends due to its diverse nuclease activity. (82) DNA-PKcs also acts to tether the two
ends of the DNA together, as well as protect the ends from degradation and prevent
premature ligation. (58,70) If the DSB is highly complex, polymerase mu and lambda are
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recruited by the Ku:DNA complex to synthesize and fill the gap. (71,73) Polymerase mu is
highly adaptable, able to perform template-dependent synthesis but can also polymerize
across a discontinuous template strand, making it well-suited for this flexible DNA repair
mechanism. (81) Polymerase lambda has also been shown to have template-independent
activity. (81) Finally, x-ray cross-complementation group 4 (XRCC4), nonhomologous endjoining factor 1 (NHEJ1), also known as XRCC4-like factor (XLF) and DNA ligase 4 seal the
ends. (58,73,83) Compared to HR, NHEJ is a highly error-prone process and its resulting
DNA product are highly mutagenic and inaccurate compared to the original sequence.
(71,83,84) If the DNA ends have at least four nucleotides of sequence homology on DNA
overhangs, XRCC4-DNA ligase 4 can simply ligate the ends of one single strand overhang
while the other is filled by polymerases, without the activity of any of the members of the
NHEJ pathway. (71,82) This scenario is the only form of NHEJ in which the original
sequence of the DNA could be preserved (Figure 9). (71,82).
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Figure 9. Non- Homologous End Joining (NHEJ). There are two main pathways of DNA
repair: NHEJ and homologous recombination. A, NHEJ. a, A DSB is recognized by the Ku
dimer (Ku70–Ku80) and DNA-PKcs. b, The two DNA ends are synapsed. c,DNA-PKcs and
Artemis are phosphorylated, and the DNA ends are processed by a complex consisting of
XLF (XRCC4-like complex; also known as NHEJ1), XRCC4 (X-ray-repair crosscomplementing protein 4) and DNA ligase IV, and by Artemis. d, The DNA ends are ligated
by DNA ligase IV, and the DNA-repair factors dissociate.
Modified and reprinted with permission from Nature Publishing Group: [Nature] (85),
Copyright 2007.
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Possible implication with PARP inhibitors
It has been shown recently that treatment with a PARP inhibitor enhanced the
phosphorylation of DNK-PKcs and therefore aberrantly activate NHEJ in ovarian cancer cell
lines. (86) The authors of this study hypothesize that the deregulated and highly mutagenic
NHEJ further increases genomic instability and cytotoxicity associated with PARP inhibition.
Therefore, in the setting of HR- deficiency, increased NHEJ activity contributes to synthetic
lethality and may predict sensitivity to PARP inhibitors (Figure 10).

Figure 10. Role of HR and NHEJ in PARP inhibition. Current model explaining synthetic
lethality of PARP inhibition and HR deficiency. PARP inhibition is thought to induce
accumulation of SSBs, which are converted to DSBs by collisions with replication
machinery. The inability of HR-deficient cells to adequately repair DSBs results in genomic
instability and eventual cell death.
Reprinted from Patel, A. G., Sarkaria, J. N. & Kaufmann, S. H. Nonhomologous end joining
drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombinationdeficient cells. Proceedings of the National Academy of Sciences of the United States of
America 108, 3406-3411, doi:10.1073/pnas.1013715108 (2011). (86)
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1.6 Hypothesis and specific aims
Although MPNSTs do not have a characterized defect in BRCA1/2 or any DNA repair
pathway deficiency, they have a karyotypically-complex phenotype that would suggest a
deficiency in DNA damage repair and a high level of inherent DNA damage and genomic
instability. (87,88) Therefore, I hypothesize that poly (ADP) ribose polymerase (PARP)
inhibition is an effective therapeutic strategy in MPNST.
To pursue this hypothesis, I developed the following specific aims:

Aim 1: Evaluate the effects of PARP inhibition on MPNST in vitro and in vivo.

Aim 2: Identify potential mechanisms underlying MPNST sensitivity to PARP
inhibitors.

27

Chapter 2
Materials and Methods

Clinically annotated tissue microarray
This study was approved by The University of Texas MD Anderson Cancer Center
Institutional Review Board. A clinically annotated tissue microarray (TMA) containing samples
of 115 human atypical and plexiform neurofibromas (n = 24) and MPNSTs (primary, n = 38;
recurrent, n = 32; MPNST, n = 21) was used for immunohistochemical staining. TMAs were
constructed as previously described. (89)
Cell lines
MPNST cell lines used in this study include three NF1-associated MPNST cell lines
(S462 [provided by Dr. Brian Rubin, The Cleveland Clinic and The Cleveland Clinic Lerner
College of Medicine, Case Western Reserve University, Cleveland, OH] and ST88 and
MPNST92-417/T265 [provided by Dr. Jonathan Fletcher, Brigham and Women’s Hospital,
Boston, MA]), and two sporadic MPNST cell lines (STS26T [provided by Dr. Steven Porcelli,
Albert Einstein College of Medicine, Bronx, NY] and MPNST724 [provided by Dr. Jonathan
Fletcher]). Primary human adult normal Schwann cell (NSC) cultures were provided by Dr.
Patrick Wood (University of Miami, Miami, FL) or purchased from ScienCell Research
Laboratories. MDA-MB-231, MDA-MB-436, and T47D breast cancer cells were purchased
from the MD Anderson Cancer Center characterized cell line core. MPNST cells were grown
in Dulbecco’s modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum
(FBS), 100U/ml penicillin, and 100μg/ml streptomycin. MPNST cell lines with Cockayne
syndrome B overexpression (CSBOE) or CSB shRNA were grown in DMEM with 10% FBS,
100U/ml penicillin, and 100μg/ml streptomycin; positive transfectants were selected with 1
μg/ml puromycin then grown under selective pressure. Schwann cells were grown in
Schwann cell media (#1701, ScienCell Research Laboratories) supplemented with 5% FBS,
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100U/ml penicillin, 100μg/ml streptomycin, and 1% Schwann cell growth supplement (#1752,
ScienCell Research Laboratories). MDA-MB-231 and MDA-MB-436 were grown in
Dulbecco’s modified Eagle medium:Nutrient mixture F-12 (DMEM F-12) supplemented with
10% FBS, 100U/ml penicillin, and 100μg/ml streptomycin. T47D cells were grown in RPMI1640 media supplemented with 5% FBS, 100U/ml penicillin, and 100μg/ml streptomycin. DNA
fingerprinting (short tandem repeat, STR) was conducted as previously described to verify
the identity of all MPNST cell lines. (90)
Antibodies and reagents
The PARP inhibitors AZD2281 was purchased from ChemieTek (CT-A2281). For in vitro
studies, the drugs were dissolved in dimethyl sulfoxide (DMSO) and stored at -80°C. For in
vivo experiments, AZD2281 (50mg/kg/day) was dissolved in PBS, 10% DMSO, and 10% 2hydroxypropyl-β-cyclodextrin (HPCD). The DNA-PK inhibitor NU7026 was purchased from
Selleck Chemicals (S2893). For in vitro studies the drug was dissolved in dimethyl sulfoxide
(DMSO) and stored at -80°C. Commercially available antibodies were used for western blot
or immunohistochemical (IHC) detection of PARP1 (9542, Cell Signaling Technology),
PARP2 (PA1-4280, ThermoFisher Scientific Pierce) and (SAB2500751, Sigma-Aldrich), PAR
(4335-AMC-050, Trevigen Inc) and (ALX-084-220-R100, Enzo Life Sciences, Inc.), gammaH2AX (2577, Cell Signaling Technology), CSB (10459, Santa Cruz Biotechnology), DNAPKcs (4602, cell signaling), DNA-PKcs Ser2056 (124918, Abcam), Ki67 (CRM325, Biocare
Medical), cleaved caspase 3 (CC3; CP229, Biocare Medical), cyclin B1 (752, Santa Cruz
Biotechnology), and β-actin-HRP (47778-HRP, Santa Cruz Biotechnology). Terminal
deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) was performed using the TdTFragEL™ DNA Fragmentation Detection Kit according to the manufacturer’s instructions
(QIA33, EMD Millipore). The pEGFP-Pem1 system HR and NHEJ plasmids were provided by
Dr. Vera Gobunova (University of Rochester, Rochester, NY). The CSB OE plasmid (pLentiGIII-CMV-hERCC6-HA; LV150273) and viral packaging vectors (LV053) were purchased
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from Applied Biological Materials British Columbia, Canada. Viral packaging was performed
by the MD Anderson Cancer Center shRNA and ORFeome Core. ERCC6 shRNA (Individual
Human SMARTvector 2.0 Lentiviral shRNA particles) were purchased from ThermoFisher
Scientific (VSH6063). Polybrene (sc-134220, Santa Cruz Biotechnology) and puromycin
(400-128P, Gemini Bio-Products) were used for shRNA transductions. Restriction enzymes,
ISCE1 and HindIII, were purchased from New England Biolabs and used according to New
England Biolabs established conditions and protocols.
ERCC6 shRNA transductions
Approximately 5x105 MPNST cells were trypsinized, centrifuged, and resuspended in 1
mL of DMEM supplemented with 5% FBS. Polybrene (1μg/ml) was added to each cell
suspension, which were subsequently plated into six well tissue culture plates. Approximately
5.0x106 viral particles were added to each well and incubated at 37°C for 8 hours. The media
was then changed to DMEM supplemented with 10% FBS and incubated at 37°C for an
additional 64 hours. Cells were grown under selective pressure (1.0µg/ml puromycin) for
subsequent experiments. Knockdown of CSB was confirmed by western blot.
MTS assays
CellTiter96 AQueous One Solution Cell Proliferation Assays [3-(4,5-dimethylthiazol-2yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt; MTS] (G3580,
Promega) were used to evaluate cell proliferation per the manufacturer’s instructions. Briefly,
cells were seeded in 96-well plates in 100µL of media. Attached cells were subsequently
treated with AZD2281 and incubated with drug for 96 hours or 7 days (drug and media
changed after 96 hours). MTS reagent was added to each well and incubated for 1-2 hours
at 37°C. Absorbance was measured at a wavelength of 490nm. The absorbance values of
treated cells were represented as a percentage of the absorbance of untreated cells. The
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half-maximal effective concentration (EC50) of AZD2281 was determined using nonlinear
regression log(inhibitor) vs. response (four parameters) curve fitting in GraphPad Prism
version 6.05.
Clonogenic assay
Clonogenic assays were conducted by plating 100-500 MPNST cells in 6-well plates.
Cells were then treated with DMSO or AZD2281 in DMEM for approximately 2 weeks. The
media was removed, and the cells were washed twice with phosphate-buffered saline (PBS).
The cells were fixed with 5% gluteraldehyde for 20 minutes and then washed and stained
with 0.1% crystal violet in 20% methanol for at least 1 hour. The wells were washed with water
and allowed to dry. Pictures were captured digitally and individual clones were counted
manually. Clones of treated cells were represented relative to the untreated control.
Western blot analysis
Western blot analyses were conducted according to previously published standard
methods. (91) Densitometry was assessed using the ImageJ Gel Analysis tool version 1.49
(NIH).
Flow cytometry
Cell cycle progression was measured by propidium iodide (PI) staining followed by
fluorescence activated cell sorting (FACS) analysis. Cells were incubated with AZD2281 for
24 hours and subsequently fixed in 70% ethanol. Fixed cells were resuspended in a PI
staining solution (75μg/mL PI and 10μg/mL RNAse A). For evaluation of apoptosis, cells were
treated with AZD2281 for 96 hours. Apoptosis was measured via Annexin V-Fluorescein
isothiocyanate (Annexin V-FITC)/PI staining and FACS analysis with the FITC Annexin V
Apoptosis

Detection

Kit

I

(556547,

BD

Biosciences)

per

the

manufacturer’s

recommendations. Cells reported as apoptotic include those in early and late phase
apoptosis. Cell cycle and apoptosis samples were analyzed with the use of a Gallios flow
31

cytometer (Beckman Coulter Inc.) by the Flow Cytometry and Cellular Imaging Core at MD
Anderson. Data from these experiments were analyzed with the use of the Multicycle program
in FCS Express (De Novo Software).
PARP activity assay
PARP activity assays were performed by using the Trevigen Universal PARP
Colormetric Assay Kit (4677-096-K, Trevigen Inc) according to the manufacturer’s instructions
with the following modifications. Cells were seeded in six-well plates at approximately 50%
confluency. The cells were then treated with AZD2281 and incubated for 24 hours at 37° C.
Endogenous PARP activity was established without AZD2281 pretreatment. Cellular protein
was extracted by scraping using the Cell Extraction Buffer (1x PARP Buffer [20X PARP buffer
provided in kit diluted in water], 0.4M NaCl, 0.9% Triton X-100, 0.4nM PMSF, cOmplete
Protease Inhibitor Cocktail Tablets [11697498001, Roche]). The suspension was centrifuged
at 4°C for 10 minutes at >10,000g; the supernatant was extracted and the protein
concentration was measured.
Histone-coated strip wells were hydrated by using 1x PARP buffer for 30 minutes at
room temperature; three wells per condition were used. The positive control wells contained
diluted PARP-HSA enzyme (provided in kit), 1x PARP buffer, and 1x PARP cocktail (10x
PARP cocktail provided in kit, 10x Activated DNA provided in kit, and 1x PARP buffer) at a
final volume of 50µl. The negative control wells contained DMSO, 1x PARP buffer, and 1x
PARP cocktail at a final volume of 50µl. The experimental wells included 10µg pretreated cell
lysate in a total volume of 25μl, and 1x PARP cocktail at a final volume of 50µl. The wells
were incubated for 1 hour at room temperature. The remainder of the experiment was
performed according to the manufacturer’s instructions. The absorbance values of three wells
from each experiment were averaged and the absorbance values of treated cells were
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represented as a percentage of the absorbance of untreated cells. The data were represented
as the average of two experiments with the standard error of the mean (SEM).
RNA sequencing
Total RNA was prepared using the RNeasy Mini Kit (74104, Qiagen) according to the
manufacturer’s protocol. RNA sequencing was performed by the MD Anderson Cancer
Center Sequencing and Microarray Facility with an Illumina HiSeq2000 sequencer. The raw
reads were aligned to the human reference genome build hg19, using Tophat2 RNASeq
alignment software. The mapping rate was 95.27% overall across all the samples in the
dataset. HTseq-Count was used to quantify the gene expression counts from Tophat2
alignment files. Differential expression analysis was performed on the count data using R
package DESeq2. P-values obtained after multiple binomial tests were adjusted using FDR
(BH).
TaqMan PCR confirmation of RNAseq results
Total RNA was extracted from cell lines using the RNeasy Mini Kit according to the
manufacturer’s protocol. RNA was converted into cDNA using the iScript cDNA synthesis kit
(1708890, Bio-Rad Laboratories) via the kit protocol. Excision repair cross-complementation
group 6 (ERCC6) expression was confirmed using TaqMan PCR (Hs00972920_m1 primer:
4331182, ThermoFisher Scientific) according to the manufacturer’s instructions.
pEGFP-Pem1 system transfection
The pEGFP-Pem1 plasmid system was a kind gift from the Vera Gorbunova laboratory
(University of Rochester). (92,93) The HR plasmid of the pEGFP-Pem1 system was linearized
by I-SceI digestion. 500ng of the linearized plasmid was transiently transfected into
approximately 5x105 cells using the Neon transfection system according to the manufacturer’s
instructions (ThermoFisher Scientific) along with the transfection control plasmid pDs-Red2
(100ng). The electroporation parameters were 1350V (pulse voltage), 20ms (pulse width), 2
pulses (pulse number) for cell lines. The cells were then plated in DMEM supplemented with
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10% FBS. GFP was measured by flow cytometry 72 hours post transfection. The pEGFPPem1 system also contains a plasmid to measure NHEJ efficiency. DSBs were induced by ISceI or Hind-III and the transfection proceeded similar to the HR plasmid. The data was
reported as a ratio of green (indicating efficient HR in the cell) to red (indicating a transfected
cell). Cells were analyzed with the use of a LSR Fortessa flow cytometer (BD Biosciences)
located in the Flow Cytometry and Cellular Imaging Core at MD Anderson. Data from these
experiments were analyzed with the use of the Multicycle program in FCS Express (De Novo
Software).
Metaphase spread
Cell lines were treated with DMSO, 2.5µM AZD2281, 500nM NU7026, or combination
treatment for 72 hours. Chromosome analysis was performed in duplicate at the UTMDACC
Molecular Cytogenetics Facility (funded by the Center for Genetics and Genomics).
Metaphase

spreads

from

each

sample

were

photographed

using

a

Nikon

80i microscope equipped with karyotyping software from Applied Spectral Imaging (ASI) Inc.
The samples were scored for structural aberrations including chromosomal breaks,
fusions, fragments, and radial structures. Thirty-five cells per plate and condition were
evaluated.
CPD ELISA
MPNST cells were plated in 6 well dishes to approximately 50% confluency. Prior to UV
exposure, the wells were washed with PBS and the media was replaced with 500µl PBS. The
dishes were then exposed to 256J/m2/min UVB using the FS40 lamp. (94) Immediately after
exposure, the 0hr time point was harvested for cell lysates and pelleted for DNA extraction
and use in the cyclobutane pyrimidine dimer (CPD) enzyme- linked immunosorbent assay
(ELISA). The media in the remaining wells was replaced with DMEM supplemented with 10%
fetal bovine serum, 100U/ml penicillin, and 100μg/ml streptomycin and harvested at the
corresponding time points. DNA extraction was then performed using the QIAamp DNA Mini
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Kit. The OxiSelect™ UV-Induced DNA Damage ELISA Kit (STA-322, Cell Biolabs) was then
carried out according to the manufacturer’s instructions.
In vivo animal models
All animal procedures and care were approved by The University of Texas MD Anderson
Cancer Center Institutional Animal Care and Usage Committee (IACUC). Animals received
humane care as per the Animal Welfare Act and the NIH "Guide for the Care and Use of
Laboratory Animals." Animal models were utilized as previously described. (95,96) Trypan
blue confirmed viable MPNST724 cells (2x106 in 0.1mL of PBS/mouse) or STS26T cells
(2x106 in 0.1mL of PBS/mouse) were injected into the flank of 6–week-old female hairless
severe combined immunodeficient (SCID) outbred mice (Crl:SHO-PrkdcscidHrhr, Strain Code:
474) (474-SCID Hairless, Charles River Laboratories) (MPNST724: vehicle group n=9 and
AZD2281 group n=8; STS26T: n=8/for each treatment group), and growth was measured
twice weekly. When average tumor volumes reached 50 mm3, the mice were assigned to two
treatment groups: (a) control (vehicle only) and (b) AZD2281. AZD2281 (50mg/kg/daily,
intraperitoneal injection [IP]) resuspended in PBS, 10% DMSO, and 10% 2-hydroxypropyl-βcyclodextrin (Sigma-Aldrich, St. Louis, MO) was used. Mice were monitored for tumor size,
body weight, and well-being, and were euthanized when control group tumors reached an
approximate volume of 1500 mm3. Tumors were resected, weighed, and fixed in formalin and
paraffin-embedded for IHC studies.
An experimental lung metastasis MPNST model was used to evaluate metastatic
growth. This model has been described previously. (96) Viable STS26T cells were injected
as cell suspensions (1x106 in 0.1mL of PBS/mouse) into the tail vein of 6–week-old female
hairless severe combined immunodeficient (SCID) outbred mice (Crl:SHO-PrkdcscidHrhr,
Strain Code: 474). Mice were monitored for 3 weeks (a time point by which 95%-100% of
mice develop established lung metastases). (97) Mice were then assigned to the following
treatment groups: (a) control (vehicle only) and (b) AZD2281 (50mg/kg/d, IP). AZD2281
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resuspended in PBS, 10% DMSO, and 10% 2-hydroxypropyl-β-cyclodextrin was used. Mice
were euthanized when physical signs of disease were present (weight loss >20% of baseline,
difficulty of breathing, hunched posture, pallor, impaired ambulation, and lethargy). Lungs
were resected, weighed, and examined for macroscopic lung metastases; these tissues were
then fixed in formalin and paraffin-embedded for IHC studies. Survival studies proceeded as
above; however, mice were sacrificed individually when euthanasia was required.
IHC analysis
PARP1 and PARP2 immunostaining was scored by two independent observers (AJL
and GAA) for TMA analyses. Intensity scores were designated as negative (0), weak (1 and
2), or strong (3). The percentage of cells staining positive was evaluated on a scale of 0100%. A combined score ranging from 0-300 was obtained from the product of the intensity
and cells-positive scores. Xenograft-derived specimens were analyzed for markers of cell
proliferation (Ki67), cell cycle arrest (cyclin B1), inhibitor specificity (PAR), and apoptosis
(CC3 and TUNEL). Representative images of the TMA and xenograft- derived specimens
were captured at 200x and 400x total magnification, respectively, using an Olympus
microscope (BX41) and camera (DP72) with Olympus cellSens Standard v1.5 software.
Statistical analyses
Differences among expression of PARP1 and PARP2 between tumor types were
evaluated using Mann-Whitney U tests. Univariate Cox proportional hazards models were
used to assess the potential prognostic significance of PARP1 expression in primary and
recurrent MPNST samples and further visualized utilizing univariate Kaplan-Meier curves.
Two-sided p-values <0.05 were considered statistically significant. All analyses were
performed using SPSS version 21.
Cellular assays were repeated at least two times; the mean and SEM were calculated
for each assay. The mean and standard deviation were calculated for xenograft experiments.
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Correlation analysis between the fold change expression of CSB and the EC50 value of
AZD2281 was established using Spearman’s correlation. Significance of findings was
assessed using a two-tailed Student's t-test (p<0.05 = *; p<0.001 = ***).
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Chapter 3
PARP inhibition in vitro and in vivo
This chapter is based upon the citation below and has been reprinted with permission from
Taylor and Francis: [Cancer Biology and Therapy], copyright 2015.
Kivlin, C. M. et al. Poly (ADP) Ribose Polymerase Inhibition: A Potential Treatment of
Malignant
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doi:10.1080/15384047.2015.1108486 (2015).
PARP1 and PARP2 are highly expressed in MPNST tissue samples.
To determine the expression of PARP1 and PARP2 in human tumor samples, we
performed IHC on a clinically annotated TMA containing patient samples of neurofibroma,
primary MPNST, recurrent MPNST, and metastatic MPNST (Figure 11). The overwhelming
majority of MPNST samples were positive for PARP staining. Overall, moderate to high
expression of PARP1 and PARP2 was observed (Table 1).

Figure 11. PARP1 and PARP2 are highly expressed in MPNST tissue compared to
neurofibroma. MPNST TMA stained for PARP1 and PARP2. Images were captured at 200x
magnification.
Reprinted with permission from Taylor and Francis: [Cancer Biology and Therapy] (98),
copyright 2015.
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Table 1. Mean expression of PARP1 and PARP2 combined score (0-300) and percentage of
tumors with positive staining in neurofibroma and MPNST.
Reprinted with permission from Taylor and Francis: [Cancer Biology and Therapy] (98),
copyright 2015.
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While there was differential expression of PARP1 and PARP2 between primary,
recurrent, and metastatic MPNST samples with regard to percent positive cells, nuclear
intensity, and combined score, the clinical relevance of these minor variations is negligible as
the overall expression levels remain high (Table 2 and Table 3).

Table 2. Mean expression of PARP1 and PARP2 percentage of staining, nuclear intensity,
and combined score in neurofibroma and MPNST disease states.
Reprinted with permission from Taylor and Francis: [Cancer Biology and Therapy] (98),
copyright 2015.
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Table 3. Summary of PARP1 and PARP2 distribution. PARP percentage of expression
and nuclear intensity was scored from the MPNST TMA. The P value to determine the
significance of distribution between disease states is shown.
Reprinted with permission from Taylor and Francis: [Cancer Biology and Therapy] (98),
copyright 2015.

In addition, we evaluated whether PARP1 expression correlated with the survival
outcomes of MPNST patients. Although not statistically significant, a trend towards better
survival was observed in patients with tumors expressing low levels of PARP1 when
compared to patients that had tumors with moderate to high expression (p = 0.165; HR 0.51,
95% CI 0.19-1.32) (Figure 12; Table 4). PARP2 was not evaluated by log-rank comparison
due to its homogenously uniform expression.
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Figure 12. PARP1 staining correlated to patient outcomes. Kaplan-Meier curve depicting
a trend toward decreased survival in patients with moderate-high levels of PARP1 staining
compared to low PARP1 staining, as determined by IHC.
Reprinted with permission from Taylor and Francis: [Cancer Biology and Therapy] (98),
copyright 2015.

Table 4. Overall and disease- specific survival outcomes for MPNST patients determined by
PARP1 percentage of staining, nuclear intensity, or combined score.
Reprinted with permission from Taylor and Francis: [Cancer Biology and Therapy] (98),
copyright 2015.
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PARP1 is highly expressed in MPNST cell lines.
Based on the enhanced expression of PARP1 and PARP2 seen in our MPNST tissue
samples, we assessed their expression in a panel of MPNST cell lines. An immunoblot of
PARP1 and PARP2 suggested increased expression in MPNST cell lines versus the normal
Schwann cell control (Figure 13).

Figure 13. PARP1 and PARP2 are highly expressed in MPNST cell lines compared to
normal Schwann cells. Immunoblot of PARP1 and PARP2 in a MPNST cell panel and
normal Schwann cell control.

PARP activity is enhanced in MPNST cell lines.
PARP1 and PARP2 modify acceptor proteins through PARylation and thus influence
their cellular function. Therefore, PAR expression can be used as a marker of PARP catalytic
activity. We performed western blot analysis to interrogate a panel of MPNST cell lines
(sporadic: MPNST724 and STS26T; NF1-associated: S462 and ST88) for endogenous PAR
expression. MPNST cell lines have enhanced PAR expression, suggestive of increased
PARP activity compared with normal Schwann cells (NSCs), with MPNST724 cells showing
the lowest expression of the MPNST cell lines (Figure 14). Because PARP activity is
stimulated by DNA damage, increased endogenous PAR expression could indicate the
relatively high levels of endogenous DNA damage in MPNST cell lines.
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Figure 14. MPNST cell lines have enhanced PAR expression. PAR immunoblot of MPNST
cell panel and normal Schwann cells.
Reprinted with permission from Taylor and Francis: [Cancer Biology and Therapy] (98),
copyright 2015.

To validate that enhanced PARP expression is representative of endogenous PARP
activity in MPNST cell lines, untreated MPNST cell lines and NSCs were used in a modified
Universal PARP Colorimetric Assay. PARP activity was found to be more than three-fold
higher in MPNST cell lines compared to NSCs in this cell-free system (Figure 15).
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Figure 15. MPNST cell lines have increased PARP activity compared to NSCs.
Endogenous PARP activity in untreated MPNST cells and normal Schwann cells (n=4). Error
bars represent standard error of the mean; (*= p<0.05).
Reprinted with permission from Taylor and Francis: [Cancer Biology and Therapy] (98),
copyright 2015.

AZD2281 is a highly effective single-agent inhibitor of MPNST in vitro.
Before assessing the effect of AZD2281 on MPNST tumorigenicity, we evaluated
the efficacy of this inhibitor to block PARP activity. A panel of MPNST cell lines was treated
with increasing doses of AZD2281 for 24 hours and evaluated by the modified Universal
PARP Colorimetric Assay. AZD2281 treatment resulted in a dose-dependent decrease in
PARP activity in all MPNST cell lines (Figure 16).
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Figure 16. PARP inhibition decreases PARP activity in MPNST cell lines. A panel of
MPNST cell lines were pretreated for 24 hours with AZD2281 and subjected to a modified
PARP activity assay (26T, ST88, and 462 n=3; 724 n=2). Error bars represent standard error
of the mean; * = p<0.05; *** = p<0.001.
Reprinted with permission from Taylor and Francis: [Cancer Biology and Therapy] (98),
copyright 2015.
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Treatment of MPNST cell lines with elevated concentrations of AZD2281 for 96 hours resulted
in a proportional decrease in cell proliferation. All EC50 values for the MPNST cell panel were
in the micromolar range (2.92 – 12 μM) with no variation in sensitivity between the sporadic
and NF1-associated cell lines. In comparison, normal Schwann cell lines treated with the
same dose of AZD2281 showed only a slight decrease in cell proliferation. EC50s ranged
from 18μM to greater than 20μM, which was the highest treatment dose used (Figure 17).
Compared to cell lines known to be sensitive or resistant to AZD2281 as determined by their
AZD2281 EC50 values, the EC50s of MPNST cell lines more closely resemble those of the
the known sensitive cell lines (Table 5). Additionally, AZD2281 decreased the clonogenic
potential of MPNST cell lines in a dose-dependent manner (Figure 18).
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Figure 17. PARP inhibition significantly inhibits MPNST cell proliferation in vitro
compared to normal Schwann cells. MPNST and NSC cell lines were treated for 96 hours
with AZD2281 and cell proliferation was assessed by MTS assay (n=3; ST88 n=4). Error bars
represent standard error of the mean; * = p<0.05; *** = p<0.001.
Reprinted with permission from Taylor and Francis: [Cancer Biology and Therapy] (98),
copyright 2015.
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Table 5. Cell line sensitivity to AZD2281. MPNST cell lines have AZD2281 EC50s more
similar to known sensitive cell lines. Cells treated with AZD2281 for 96 hours and assessed
by MTS assays to acquire EC50 values.

Figure 18. AZD2281 treatment decreases the clonogenic potential of MPNST cells.
Representative images of clonogenic assays wells. Graph of replicate experiments with
clones of treated cells represented relative to the untreated control (724 n=2; 462 and ST88
n=4; 26T n=5). Error bars represent standard error of the mean; (*=p<0.05; ***=p<0.001).
Reprinted with permission from Taylor and Francis: [Cancer Biology and Therapy] (98),
copyright 2015.
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Based on the reduced cell proliferation and clone-forming ability observed, we wanted
to evaluate cell cycle distribution and apoptosis after AZD2281 treatment. A significant
increase in the G2/M phase of the cell cycle was observed following a 24-hour treatment with
AZD2281 (Figure 19).

Figure 19. AZD2281 induces a dose-dependent cell cycle arrest. PI FACS analysis after
24 hour treatment with AZD2281 in MPNST cell lines (26T and ST88 n=3; 724 and 462 n=4).
Error bars represent standard error of the mean; (*=p<0.05).
Reprinted with permission from Taylor and Francis: [Cancer Biology and Therapy] (98),
copyright 2015.
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This analysis also revealed that AZD2281 induced apoptosis in MPNST cells after 96 hours
of treatment (Figure 20). These in vitro responses prompted us to evaluate the functional
effects of PARP inhibition on MPNST tumor growth.

Figure 20. AZD2281 induces apoptosis in a dose-dependent manner. Annexin V-FITC/PI
FACS analysis after 96 hour AZD2281 treatment in MPNST cell lines (n=3). Error bars
represent standard error of the mean; (*=p<0.05).
Reprinted with permission from Taylor and Francis: [Cancer Biology and Therapy] (98),
copyright 2015.
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AZD2281 decreases MPNST local tumor growth
To evaluate the effect of AZD2281 on MPNST local tumor growth, we utilized two
subcutaneous xenograft mouse models using the MPNST724 and STS26T cell lines. Mice
were treated with daily 50mg/kg AZD2281 (n=8) or vehicle (n=9) (IP). AZD2281 treatment
significantly reduced tumor volume and weight compared to the vehicle group (Figure 21 and
Figure 22). The effects of AZD2281 treatment were validated by IHC analyses. AZD2281
resulted in a decrease in cell proliferation as measured by Ki67 staining. Furthermore, a
decrease in the intensity of PAR staining was observed after AZD2281 treatment, supporting
the specificity of the inhibitor for PARP enzymatic activity. Increased cyclin B1 staining
suggested an accumulation of cells in the G2/M phase. Furthermore, an increase in tumor
cell apoptosis (indicated by TUNEL and CC3 positivity) was found after PARP inhibition.
These results support our observations in vitro: that MPNST724 cells were slightly more
sensitive to PARP inhibition than STS26T cells.
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Figure 21. AZD2281 abrogates local tumor growth in a MPNST724 model. Seventeen
female hairless SCID mice were injected with 2x106 MPNST724 cells and treated with
AZD2281 for 23 days. Treatment groups included vehicle (10% HPCD, 10% DMSO, and
PBS) (n=9) and 50mg/kg/day AZD2281 (n=8). Tumor volume and weight were assessed.
Tumor samples were stained for Ki67, PAR, cyclin B1, CC3, and TUNEL. Original photos
were captured at 400X magnification. Error bars represent standard deviation; *** = p<0.001.
Reprinted with permission from Taylor and Francis: [Cancer Biology and Therapy] (98),
copyright 2015.
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Figure 22. AZD2281 abrogates local tumor growth in a STS26T model. Sixteen female
hairless SCID mice were injected with 2x106 STS26T cells and treated with AZD2281 for 19
days. Treatment groups included vehicle (10% HPCD, 10% DMSO, and PBS) (n=9) and
50mg/kg/day AZD2281 (n=8). Tumor volume and weight were assessed. Tumor samples
were stained for Ki67, PAR, cyclin B1, CC3, and TUNEL. Original photos were captured at
400X magnification. Error bars represent standard deviation; *** = p<0.001.
Reprinted with permission from Taylor and Francis: [Cancer Biology and Therapy] (98),
copyright 2015.
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PARP inhibition reduces experimental MPNST lung metastases
MPNSTs have a strong propensity to metastasize, primarily to the lung, within two years
of initial disease presentation; therefore, we evaluated whether PARP inhibition would affect
metastatic growth. (99,100) Because our established mouse models do not spontaneously
metastasize, we utilized an experimental lung metastasis model as previously described. (96)
After 21 days of treatment the experiment was concluded; at this time all mice in the vehicle
group had macroscopic MPNST lung metastases, whereas 3 out of 7 (43%) had macroscopic
metastases in the treatment group. However, microscopic lung metastases were detected in
all samples, regardless of treatment. No significant difference in lung weight between
treatment groups was observed (Figure 23).

Figure 23. AZD2281 decreases macroscopic metastasis growth but does not affect
lung weight. Mice were injected via tail vein with STS26T cells and subsequently treated with
vehicle (n=7) or AZD2281 (n=7) for 21 days. Percentage of macroscopic and microscopic
lung metastases in vehicle and AZD2281-treated mice. Representative images of gross lung
and H&E staining. Graph of lung weights in the vehicle and treatment groups, mean and SEM
depicted in the scatter plot (p=0.47).
Reprinted with permission from Taylor and Francis: [Cancer Biology and Therapy] (98),
copyright 2015.
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AZD2281 long-term treatment increases survival
We then evaluated whether AZD2281 treatment affected survival in a metastatic setting.
To answer this question, we utilized the experimental lung metastasis model used in the prior
section, but sacrificed the animals individually when euthanasia was mandated due to weight
loss >20% of baseline, difficulty of breathing, hunched posture, pallor, impaired ambulation,
or lethargy. Overall, treatment continued for 60 days at which point 5 out of 7 (71%) mice in
the AZD2281 treatment group were alive versus 0 out of 7 (0%) mice in the control group
(Figure 4). These results indicated that treatment with AZD2281 significantly increased the
survival of mice with metastatic disease.
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Figure 24. AZD2281 significantly improves survival in an in vivo model of metastatic
MPNST. Female hairless SCID mice were injected with STS26T cells in the tail vein and
treated with AZD2281 for 60 days. Treatment groups included vehicle (10% HPCD, 10%
DMSO, and PBS) and 50mg/kg/day AZD2281. (*=p<0.05).
Reprinted with permission from Taylor and Francis: [Cancer Biology and Therapy] (98),
copyright 2015.
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Chapter 4
Mechanisms of PARP inhibition sensitivity
This chapter is based upon the citation below.
Kivlin, C. M. et al. A Potential Mechanism of Malignant Peripheral Nerve Sheath Tumor
Sensitivity to Poly (ADP) Ribose Polymerase Inhibition. In preparation.
Multiple possible mechanisms of cancer cell line sensitivity to AZD2281
A review of the literature from 2005 to 2015 revealed several dysregulated or mutated
DNA damage signaling and repair genes that are associated with AZD2281 sensitivity in their
respective models (Table 6). This prompted us to evaluate not only the specific DNA repairrelated genes dysregulated in MPNST, but also the efficiency of DNA double strand break
repair pathways, specifically HR and NHEJ.

Table 6. Mechanisms of sensitivity for AZD2281. Published mechanisms of sensitivity for
AZD2281 from 2005-2015.
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MPNST cell lines have DNA repair pathway deficiencies
To interrogate the efficiency of NHEJ and HR in MPNST cell lines, we used the pEGFPPem1 plasmid system established by V. Gorbunova. (92,93) The HR plasmid of the pEGFPPem1 system is a reporter cassette that consists of two mutated copies of GFP-Pem1. In the
first copy the green fluorescent protein (GFP) exon contains a 22 nucleotide deletion,
therefore GFP cannot be reconstituted by a NHEJ event, and an insertion of two I-SceI
recognition sites in inverted orientation. The second copy of GFP-Pem1 lacks the ATG start
codon and the second exon of GFP (Figure 25). Upon induction of DSBs by I-SceI, a
restriction enzyme (RE), the linearized plasmid is transiently transfected into the cells along
with the transfection control plasmid pDs-Red2. Intact homologous recombination can then
reconstitute an active GFP gene. GFP and RFP expression are reported as a ratio of green
(indicating effective HR in the cell) to red (indicating a transfected cell).

Figure 25. Reporter construct of the HR plasmid of the eGFP-Pem1 system. Reporter
plasmid for analysis of HR. The reporter cassette consists of two mutated copies of GFPPem1. In the first copy of GFP-Pem1, the first GFP exon contains a deletion of 22 nt and an
insertion of two I-SceI recognition sites in inverted orientation. The 22 nt deletion ensures that
GFP cannot be reconstituted by a NHEJ event. The second copy of GFP-Pem1 lacks the
ATG and the second exon of GFP. Upon induction of DSBs by I-SceI, gene conversion events
reconstitute an active GFP gene.
Reprinted with permission from Elsevier: [Neoplasia] (93), Copyright 2009.
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The eGFP-Pem1 system also contains a plasmid to measure NHEJ efficiency. GFP is
separated by a 2.4 kb Pem1 intron containing an adenoviral exon that is flanked by HindIII
and I-SceI restriction sites. The adenoviral exon inactivates the GFP activity, making the
starting substrate GFP negative. Both sides of the adenoviral exon have HindIII/I-SceI
restriction sites. Cleavage with either RE removes the Ad exon and if the cells have intact
NHEJ, full length GFP will be expressed. Digestion with HindIII generates compatible ends
which NHEJ can simply re-ligate; cleavage with I-SceI generates incompatible ends which
need to be processed by NHEJ nucleases and polymerases before ligation (Figure 26).
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Figure 26. Reporter construct of the NHEJ plasmid of the eGFP-Pem1 system. Reporter
plasmid for analysis of NHEJ. The reporter cassette consists of a GFP gene under a
Human cytomegalovirus (CMV) promoter with an engineered intron from the rat Pem1 gene,
interrupted by an adenoviral exon (Ad). The adenoviral exon is flanked by I-SceI recognition
sites in inverted orientation for induction of DSBs. In this construct, the GFP gene is inactive;
however, upon induction of a DSB and successful NHEJ, the construct becomes
GFP+. SA indicates splice acceptor; SA, splice donor; shaded squares, polyadenylation
sites. HindIII generates compatible ends. I-SceI generates incompatible ends.
Reprinted with permission from Elsevier: [Neoplasia] (93), Copyright 2009 and reprinted from
Fattah, F. et al. Ku regulates the non-homologous end joining pathway choice of DNA doublestrand

break

repair

in

human

somatic

cells.

PLoS

genetics

6,

e1000855,

doi:10.1371/journal.pgen.1000855 (2010).
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We used T47D breast adenocarcinoma cells as a positive control for the NHEJ and HR
plasmids. MDA-MB-231 and MDA-MB-436 breast adenocarcinoma cell lines were used as a
positive and negative control for the HR plasmid, respectively. There was no striking
difference in the NHEJ efficiency of all MPNST cell lines compared to the T47D control; with
S462 having the greatest NHEJ efficiency. However, MPNST cell lines had HR levels similar
to the MDA-MB-436 cell line, known to be HR deficient due to a BRCA1 mutation (101), and
substantially lower levels than the HR-intact MDA-MB-231 and T47D cell lines (Figure 27).
This indicates that MPNST cells lines have deficient HR which could contribute to their PARP
inhibitor sensitivity. Furthermore, the activity of NHEJ in MPNST could also contribute to
PARP inhibitor sensitivity by increasing the amount of inherent chromosomal instability in
these cells.

Figure 27. MPNST cell lines have deficient HR repair. Cells were transfected with the
NHEJ or HR eGFP-Pem1 plasmid and incubated for 72 hours. Green fluorescence indicates
intact NHEJ or HR, and red fluorescence represents transfection efficiency. Fluorescence
was assessed by flow cytometry. Error bars represent SEM (n=2). (*=p<0.05).
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PARP inhibition enhances NHEJ activity which results in increased chromosomal
instability.
Patel et al. showed that in homologous recombination deficient ovarian cancer cell lines,
PARP1 acted as a negative regulator of NHEJ activity. (86) Although NHEJ is an efficient
method of double strand DNA repair, because it does not utilize a template strand for repair,
it is an inherently error- prone mechanism. They suggest that in HR deficient cell lines that
have been treated with a PARP inhibitor, despite the accumulation of unresolved DNA DSBs
that develop, which are highly toxic to the cell, the main cause of cell death is the enhanced
genomic instability due to increased activity of NHEJ. They further show this by blocking
NHEJ with a DNA-PKcs inhibitor, which reversed the NHEJ activity and genomic instability
and lethality of PARPi even in HR deficient cells. Therefore, treatment with a PARP inhibitor
causes increased activity of NHEJ and consequently increased chromosomal instability due
to the errors induced by NHEJ. This instability can stall the replication fork and eventually
lead to collapse of the replication fork and cell death. To determine if PARP inhibition
increases NHEJ activity in MPNST, we treated cells with AZD2281 for 72 hours and
performed an immunoblot for DNA-PKcs Ser2056. In contrast to Patel et al. which showed
no endogenous activation of DNA-PKcs, MPNST cell lines had a strong baseline expression
of DNA-PKcs Ser2056. We observed stable expression of phosphorylated DNA-PKcs with
increasing doses of AZD2281 treatment, indicating no change in DNA-PKcs activity (Figure
28). Furthermore, 72 hour treatment with increasing doses of the DNA-PKcs inhibitor,
NU7026, decreased phosphorylated DNA-PKcs (Ser2056) in a dose dependent manner,
showing the efficacy of this inhibitor.
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Figure 28. NU7026 decreases DNA-PKcs activity. Cells were treated with DMSO, 1.255µM AZD2281 and 250-4000nM NU7026 for 72 hours then immunoblotted for DNA-PKcs
(Ser2056) and total DNA-PKcs.

We then wanted to determine if treatment with a NU7026 could decrease the NHEJ
activity enhanced by PARP inhibition. Therefore, we treated MPNST cell lines with 2.5 µM
AZD2281, 500 or 1000nM NU7026, or a combination with two different doses of NU7026
(500- low combination or 1000nM- high combination) for 72 hours and performed an
immunoblot for DNA-PKcs Ser2056. We observed stable phosphorylated DNK-PKcs
expression with AZD2281 treatment alone, with a slight decrease in expression when the two
inhibitors were combined, especially at the higher combined dose. (Figure 29). This
substantiates a slight role for AZD2281 in the increase of NHEJ activity.
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Figure 29. Combination treatment decreases DNA-PKcs activity. Cells were treated with
DMSO, 2.5µM AZD2281, 500nM NU7026, or combination for 72 hours then immunoblotted
for DNA-PKcs (Ser2056) and total DNA-PKcs.
To further determine the effect of PARP inhibition on MPNST chromosomal instability,
we treated MPNST cell lines with AZD2281 and NU7026, alone and in combination, and
performed a chromosomal analysis via metaphase spread. These cells were scored for
chromosomal breaks, fragments, fusions, and radial structures, all markers of genomic
instability. In the untreated control we determined the base line level of genomic instability in
each MPNST cell lines. Treatment with AZD2281 alone caused a substantial increase the
observed chromosomal breaks, indicating increased genomic instability. Treatment with
NU7026 only marginally increased the level of genomic instability from base line. However,
dual treatment showed a varied cell line-specific effect in the number of chromosomal breaks
compared to the AZD2281 treatment group, with S462 showing the greatest decrease in
NHEJ after combination treatment (Figure 30). This could indicate that the damage induced
by PARP inhibition in MPNST cell lines that leads to cell death is partly due to NHEJ activity
which causes chromosomal instability and that altered dosing could further enhance the effect
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of combination treatment.

Figure 30. PARP inhibition increases chromosome breaks which is mitigated by
combination treatment. Cells were treated with DMSO, 2.5µM AZD2281, 500nM NU7026,
or combination for 72 hours then analyzed for chromosomal aberrations, including
chromosomal breaks (red arrow), fusions (green x), fragments (blue asterisk), and radial
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structures, via metaphase spread. Representative images and graphs of total chromosomal
breaks are shown.
Several DNA repair-related genes are dysregulated in MPNST cell lines relative to NSCs
Due to the overwhelming evidence in the literature that cells are sensitive to PARP
inhibition when there is a deficiency in a DNA repair gene, we assessed the expression level
of DNA repair-related genes in MPNST cell lines compared to NSCs using RNA sequencing
(RNAseq). (102) As a deficiency in HR or other DNA repair gene defects combined with a
PARP inhibitor is strongly associated with synthetic lethality, we chose to focus on
downregulated DNA repair-related genes. The top five downregulated genes, based on log2
fold change in at least two out of the four MPNST cell lines assessed, are shown in Table 7.
Relative to NSCs, ERCC6, essential for the transcription coupled repair sub-pathway of NER,
is the most downregulated DNA repair-related gene. Likewise, the fifth most downregulated
gene, ERCC5, is an endonuclease essential for the common pathway of NER. The other top
downregulated genes are involved in HR during meiosis (MutS Homolog 4 (MSH4) and DNA
Meiotic Recombinase 1 (DMC1)), as well as regulation of the circadian clock (Period
Circadian Clock 1 (PER1)). These results indicate multiple dysregulated DNA repair pathways
in MPNST cell lines that could contribute to the observed PARP inhibitor sensitivity.

Table 7. Downregulated DNA repair-related genes in MPNST cell lines. RNA sequencing
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results for DNA repair-related genes in MPNST cell lines versus an NSC control. No change
(NC) indicates no significant differential expression.

ERCC6 has decreased transcript and protein expression in MPNST cell lines
To validate the RNAseq results that indicate a substantial decrease in ERCC6
expression, we performed qRT-PCR for our MPNST cell panel. There is decreased transcript
expression of ERCC6 detected in MPNST cell lines versus a NSC control (Figure 31).

Figure 31. ERCC6 transcript levels are lower in MPNST cell lines. A panel of MPNST cell
lines were assessed by qRT-PCR for ERCC6 expression versus a NSC control. Error bars
represent SEM (n=3). (*=p<0.05).
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To further confirm our results, we performed immunoblot analysis for CSB, the protein
encoded by ERCC6, using an NSC and MPNST cell panel. Full-length CSB is approximately
168 kDa, while the CSB-PGBD3 fusion protein (first five exons of CSB and the piggyBac
transposable element derived 3) is 140kDa. This fusion protein has not been shown to have
a direct role in DNA repair; however, there could be an indirect effect through incorporation
of the fusion protein instead of the full-length CSB which could limit effective repair of the
DNA. (103) Fold change (FC) is determine by densitometry and is relative to each sample’s
β-actin and adjusted to the NSC9674 sample present on both immunoblots. This revealed an
average relative CSB expression of 2.5 in the NSC group versus 0.4 in the MPNST group,
showing that NSCs have an overall greater expression of CSB as well as overall higher
AZD2281 EC50 values (Figure 32). Interrogation by Spearman’s rank correlation revealed a
positive correlation between FC and AZD2281 EC50 (r = 0.645; p = 0.0368), indicating a
potential link between CSB expression and sensitivity of MPNST cell lines to AZD2281.

Figure 32. ERCC6 has decreased protein expression in MPNST cell lines. Immunoblot
of CSB in a panel of NSC and MPNST cell lines. Fold change (FC) was determine by
densitometry and is relative to each sample’s actin and adjusted to the NSC9674 sample;
(*=p<0.05). Spearman’s correlation was used to determine if CSB fold change correlated to
AZD2281 EC50; (r = 0.645; *=p<0.05).
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Alteration of CSB expression influences cancer cell line sensitivity to AZD2281
Based on the correlation of CSB expression to AZD2281 EC50, we stably
overexpressed CSB in MPNST cell lines in order to determine if there is an effect on sensitivity
to PARP inhibition. MPNST cell lines were transduced with a CSB lentiviral vector in two
separate transduction pools. Immunoblot confirmation of full length CSB overexpression was
performed in each cell line. After a 7 day treatment with AZD2281, cell proliferation was
measured by MTS assay (Figure 33). In S462 and ST88 cells, overexpression of CSB caused
an increase in the AZD2281 EC50 values Overall this shows a more prominent role for CSB
in the sensitivity of these MPNST cells to PARP inhibition. However, in STS26T and
MPNST724 cells, the overexpression of CSB has a minimal effect on the cell sensitivity to
PARP inhibition. This suggests that although CSB expression affects MPNST sensitivity to
AZD2281, there may be other players involved in the tumor cell response to treatment.

Figure 33. CSB overexpression causes a subset of MPNST cell lines to be less
sensitive to PARP inhibition. Immunoblots of CSB show increased expression of CSB after
transduction of the lentiviral vector; n=3.
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As a proof of principle that CSB expression affects PARP inhibitor (PARPi) sensitivity,
we stably knocked down CSB via shRNA in the MDA-MB-231 cell line, known to be relatively
resistant to PARP inhibition (Figure 34). (104) Knockdown of CSB caused a 3-6 fold decrease
in the EC50 of AZD2281, further substantiating a role for CSB in PARPi sensitivity.

Figure 34. CSB knockdown causes MDA-MB-231 cells to be more sensitive to AZD2281.
Immunoblots of CSB show decreased expression of CSB after transduction of the CSB
shRNA; n=3.
CSB does not affect the efficiency of CPD repair
To examine the functional effect of CSB expression, we used an ELISA (Cell Biolabs)
recognizing cyclobutane pyrimidine dimers (CPDs), one of the main types of DNA damage
induced by UV and repaired by the NER pathway. After treatment with 256J/m2/min of
ultraviolet B (UVB), we harvested the cells from 0-24 hours, a time frame in which the majority
of CPDs should be repaired, and assessed the level of CPDs (Figure 35). (105) While we
expected overexpression of CSB to increase the efficiency of CPD repair compared to the
non-targeting cells, we did not see a significant difference in the level of CPDs in the S462 or
MPNST724 cell lines. Along the same lines, we also anticipated that the knockdown of CSB
in the MDA-MB-231 cell line would decrease CPD repair efficiency compared to the nontargeting cells, but in general, observed no drastic change.
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To ensure that any decreased CPD levels seen in our ELISA was due to repair of the
damage and not conversion to a double strand DNA break, we also evaluated the expression
of gamma-H2AX in the UV treated cells from 0-24 hours. However, the expression pattern of
gamma-H2AX was similar in each cell line regardless of CSB expression.

Figure 35. Alteration of CSB expression does not affect the efficiency of CPD repair.
Cells were treated with 256J/m2/min UVB then harvested from 0-24 hours and used for CPD
ELISA and gamma-H2AX immunoblot. Error bars represent standard error of the mean (n=2);
(*=p<0.05).
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Chapter 5
Discussion, Conclusions, and Future Directions
MPNST is an aggressive subtype of STS for which surgical resection has been the
standard of care for decades and continues to be the most effective treatment. Standard
chemotherapy and radiotherapy have shown modest therapeutic benefit, restricted mostly to
local control and disease stabilization. MPNSTs have a complex karyotype indicating a high
baseline level of genomic instability and a potential DNA repair defect. Despite identification
of chromosomal aberrations and specific recurring genetic alterations which could be targeted
for therapeutic gain, several clinical trials have been conducted in MPNST and other sarcoma
subtype patients with minimal observed responses. (7,19-22,106-108) The aggressive nature
of the disease is depicted in the dismal five-year survival rate of only 35-60%. Therefore, a
novel targeted therapy is necessary to improve MPNST patient outcome.
PARP inhibitors have been shown to be efficacious in two settings: by exploiting a
genetic defect in the cells through synthetic lethality, especially a BRCA1/2 mutation or
‘BRCAness’, and as a chemosensitizer to a conventional chemotherapy or radiotherapy. (46)
AZD2281, a well-established PARP inhibitor, has been used in multiple preclinical studies
including those in breast and lung cancer, and glioma models. (49,109,110) Furthermore, this
inhibitor is now in Phase III clinical trials.
To determine the utility of PARP inhibition in MPNST, we first evaluated the expression
of PARP1 and PARP2 in neurofibroma and MPNST human tumor samples using a clinically
annotated TMA. Overall, we found that all MPNST samples had a high level of PARP1 and
PARP2 expression. PARP1 expression has been shown to be elevated in multiple
malignancies including breast, ovarian, uterine, and lung; however, PARP2 has less variable
expression patterns between normal and tumor tissue. (111,112) The increased level of
PARP expression, as well as its ubiquitous expression pattern, supports the potential use of
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PARPis in MPNST; however, the applicability of PARP staining to determine MPNST
progression is limited. PARP2 was homogenously expressed in our MPNST TMA and
therefore was not further evaluated. However, moderate to high PARP1 expression was
shown to correlate with a worse patient prognosis, although no statistical significance was
reached. This is similar to reports concerning breast cancer patients in which PARP1
overexpression correlated with reduced disease-specific survival. (113,114) This suggests
that MPNST patients with a high level of PARP1 expression would not only be a candidate
for PARP inhibition treatment, but also warrant a more aggressive treatment plan or closer
monitoring due to the more aggressive disease phenotype observed with increased PARP1
staining. While these findings are intriguing, further evaluation is necessary to determine any
clinical use of PARP staining in MPNST. Future studies should also consider larger MPNST
populations to provide more statistical power, and include clinicopathologic factors (such as
age, tumor location, tumor size, etc.) to correlate to PARP expression to find more/any
associations.
In this study, we evaluated the efficacy of the PARP inhibitor, AZD2281, in MPNST. We
show that AZD2281 has a strong anti-MPNST effect as a single agent in vitro. Specifically,
AZD2281 treatment decreased cell proliferation, at similar or lower concentrations than those
used in models with established sensitizing genetic aberrations, and at comparable or shorter
time points. (53,115,116) Furthermore, we observed that AZD2281 caused a substantial
dose-dependent cell cycle arrest at 24 hours and significantly enhanced apoptosis at 96
hours. This effect on the cell cycle and viability has been similarly observed after PARP
inhibitor treatment in BRCA2 deficient esophageal squamous carcinoma cells and BRCA1/2
deficient breast cancer cell lines, among others. (41,117) All MPNST cell lines tested have
EC50 values in the micromolar range, and no sensitivity predilection between sporadic and
NF1-associated cell lines was observed.
To further determine whether PARP inhibition would be a useful therapeutic option, we
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established the level of PARP1, PARP2, and PAR expression in a panel of MPNST cell lines
using Western blotting. Increased PARP1, PARP2, and PAR expression was observed in
MPNST cell lines compared to NSCs indicating PARP is a viable therapeutic target in
MPNST. Of the MPNST cell line panel, MPNST724 cells had the lowest PAR expression. We
further determined PARP activity using the modified PARP activity assay and observed
uniform increased endogenous PARP activity in our MPNST cell lines compared to NSCs.
Perhaps the discrepancy in the level of MPNST724 PARP activity between the immunoblot
and the PARP activity assay is due to the cell-free nature of the PARP activity assay indicating
true endogenous activation of PARP in MPNST724 cells is not as substantial. Furthermore,
inhibition of PARP via AZD2281 pretreatment, decreased PARP activity in a dose-dependent
manner in all MPNST cell lines, with MPNST724 cells showing the lowest response, further
indicating its lower overall PARP activity level compared to the other MPNST cell lines.
Interestingly, it has been suggested that increased PARP expression correlates with
increased sensitivity to PARP inhibition. (118) In the setting of MPNST, MPNST724 cells
displayed the greatest sensitivity to AZD2281 with an EC50 of 2.76µM. However, these cells
also have the lowest level of PAR expression and response of PARP activity to AZD2281
treatment. This indicates that while increased PARP activity may not always correlate with
increased sensitivity to PARP inhibition.
Based on these promising in vitro results, we evaluated AZD2281 in several in vivo
models of MPNST. To assess the effect of PARP inhibition on local tumor growth, we treated
MPNST724 and STS26T subcutaneous xenograft mouse models starting at an average
volume of 50mm3. While other studies with xenograft mouse models begin treatment when
tumors reach approximately 200mm3, due to the rapid growth rate of untreated MPNST
xenografts, we began treatment at a smaller volume in order to treat the mice for a meaningful
amount of time before a tumor volume mandating euthanasia was reached. (49,96)
Furthermore, MPNST patients, particularly those with NF1, can present with tumors greater
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than 5cm at the time of diagnosis, therefore experimental treatment of a more established
mass can better recapitulate this clinical presentation. (7) Three-week treatment of mice with
AZD2281 resulted in a significant decrease in tumor growth compared to the untreated group
and, interestingly, MPNST724 cells were more responsive to treatment than the STS26T.
Although no disease regression was observed, PARP inhibition seemed to slow the
progression of tumor growth. A previous report in a BRCA wild-type ovarian cancer xenograft
also showed decreased progression of disease with AZD2281 treatment rather than disease
regression. (119) The IHC analysis of subcutaneous tumors from both cell lines revealed a
decrease in cell proliferation, as determined by lower Ki67 expression; specific targeting of
PARP enzymatic activity as evidenced by decreased PAR staining; a possible G2/M phase
cell cycle arrest indicated by increased cyclin B1 staining; and increased CC3 and TUNEL
indicating induced apoptosis with AZD2281 treatment. These results show the potential
benefits of PARP inhibition treatment for local MPNST disease. An orthotopic model of
MPNST has been described in which tumor cells are injected into the sciatic nerve that more
faithfully recapitulates the human disease and local tumor growth; however, this model has
not been reproducibly established at our institution. (120) Future endeavors should explore
this and other orthotopic models available to expand the potential utility of AZD2281 in vivo.
Despite the high metastatic potential of MPNST which contributes to the aggressive
nature of the disease, mouse models of MPNST do not incur spontaneous metastases.
Therefore, to pursue the effect of PARP inhibition on metastasis in vivo, we used an
experimental metastasis tail vein injection model using STS26T cells. We observed a
decrease in the development of macroscopic lung metastases after PARP inhibition. All mice,
regardless of treatment, had microscopic lung metastases suggesting that AZD2281
treatment slowed the growth of lung metastases but did not cause disease regression. Based
on the observed effect of PARP inhibition on local MPNST growth in our mouse models, this
was expected. In our experimental lung metastasis model, treatment begins three weeks after
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the tail vein injection in order for micrometastases to be present. In this way, we are measuring
the ability of MPNST cells to establish and proliferate in the lung versus a true metastatic
cascade. Still, up to 50% of MPNST patients, especially those with NF1, can present with
metastatic disease at the time of initial diagnosis, therefore this mouse model may be relevant
to this clinical setting. (7)
The experimental metastasis model was also used to evaluate survival to determine
how AZD2281 might benefit MPNST patients with disseminated disease. We treated the
animals with AZD2281 following the tail vein injection and sacrificed individual mice only when
signs of disease were present. Approximately 70% (5/7) of animals that received AZD2281
treatment survived with lung metastases, compared to 0% (0/7) in the control group. These
results highlight the use of PARP inhibition as a potential MPNST therapeutic strategy to
manage metastatic lung growths, which could expand the potential application of PARP
inhibitor treatment. There are several current clinical trials evaluating the effect of PARP
inhibitor treatment in metastatic disease, including advanced solid tumors and triple negative
breast cancer; metastatic MPNST patients could therefore be incorporated in this type of trial.
Furthermore, approximately 20-54% of patients with malignancies, most notably
osteosarcoma, melanoma, and Ewing’s sarcoma, will develop lung metastases. (121)
Therefore, PARP inhibitor treatment could be evaluated in these tumors, especially those with
a characterized DNA repair defect, for potential benefit, not only for the primary lesion, but
progressive disease to the lung.
Based on the exciting inhibitory activity of single agent AZD2281 in MPNST, we wanted
to determine what genetic mutations or dysregulations led to sensitivity to this drug. Several
mechanisms of sensitivity to AZD2281 have been reported in a variety of disease models;
specifically, mutations in ATM, BRCA1 and BRCA2, PTEN, RAD51C, and RAD51D.
(49,116,122-127) All of these genes are involved in the cellular response to DNA damage or
the repair of double strand DNA breaks. Furthermore, in keratinocytes, PTEN downregulation
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has been shown to impair GGR, a subpathway of nucleotide excision repair, by suppressing
the expression of XPC, highlighting the possible links between DNA repair pathways. (128)
In addition, X. Yang et al. recently showed the sensitivity of a HR-intact pancreatic
adenocarcinoma cell line, JF-305, to AZD2281, indicating potential mechanisms of cellular
sensitivity to PARP inhibition beyond HR defects that are yet to be elucidated. (129) To
determine a potential mechanism of sensitivity of MPNST to AZD2281, we began by
evaluating the level of HR and NHEJ repair in our cell lines.
HR and NHEJ efficiency was determined using the eGPF-Pem1 plasmid system which
requires the transient transfection of a transfection control plasmid, pDs-Red2, and either a
linearized HR plasmid or linearized NHEJ plasmid. Our results indicate HR repair levels of
MPNST cell lines are similar MDA-MB-436 cells which have a known HR deficiency. In
addition, the NHEJ activity of the MPNST cell lines were similar to the control T47D cells with
proficient NHEJ repair. Therefore, although no specific mutations or dysregulations in HR
genes have been reported in MPNST, there is decreased HR activity that could contribute to
the observed MPNST sensitivity to AZD2281. In addition, the increased activity of NHEJ could
further enhance MPNST sensitivity to PARP inhibition by augmenting chromosomal
instability.
It has been shown that treatment of HR-deficient cells with a PARP inhibitor, can
increase the activity of NHEJ, and due to its error-prone nature, increase the level of genomic
instability of the cells. (86) To determine if NHEJ has increased activity in MPNST cell lines
after PARP inhibition, we first treated our cells with AZD2281. We observed stable activation
of DNA-PKcs, a critical member of NHEJ repair, via immunoblot expression of DNA-PKcs
Ser2056, and also increased chromosomal aberrations via metaphase spread analysis.
Ser2056 of DNA-PKcs is an autophosphorylation site that is required for the full activation of
DNA-PKcs and acts to limit end resection in the cell and therefore promote NHEJ over HR.
(130-132) To determine if the increased chromosomal damage after AZD2281 treatment was
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due to increased NHEJ activity, we treated our cells with two combinations of AZD2281 and
NU7026. Dual treatment decreased the amount of phosphorylated DNA-PKcs expression,
especially with the highest dose combination, but altered the amount of observed
chromosomal breaks in a cell line-specific manner. The S462 cell line had the highest level
of NHEJ as shown by the eGFP-Pem1 plasmid system, therefore perhaps the large observed
reduction in chromosomal damage after dual treatment could be due to its enhanced
endogenous NHEJ. For this cell line the sensitivity to PARP inhibition could, in part, be due
to the increase in NHEJ activity and subsequent genomic instability that results from its errorprone activity. In addition, the increased/ steady level of chromosomal breaks observed in the
remaining cell lines after dual treatment could be due to increased chromosomal damage due
to inhibition of an additional DNA repair pathway, NHEJ. However, perhaps a more substantial
inhibition of chromosomal damage could have been achieved by pretreating the cells with the
DNA-PKcs inhibitor, NU7026, prior to AZD2281 treatment.
To further evaluate DNA repair gene expression in MPNST, we performed RNA
sequencing of our MPNST cell lines. Due to the sensitivity mechanisms reported, we focused
the investigation of our RNAseq results to reported DNA repair-related genes. (102) We
expected to see decreased expression of DNA repair genes that would cause synthetic
lethality with PARP inhibition, specifically those involved in HR, in our MPNST cell lines
compared to a NSC control. However, our results indicate the majority of DNA repair-related
genes were overexpressed in MPNST cell lines, including EXO1, PCNA, RPA3, BRCA1, and
UNG, which were among the top overexpressed DNA repair-related genes in three out of four
MPNST cell lines evaluated. This observation corresponds to previous findings that MPNSTs
have a higher expression of DNA repair genes compared to plexiform neurofibromas, the
precursor benign lesion of NF1-associated MPNST. (133) This could further indicate an
increased inherent level of DNA damage in MPNST. However, future experiments will be
required to determine the status of these genes beyond expression, such as mutation and
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functional status. Several DNA repair-related genes were downregulated in at least 2 out of
4 MPNST cell lines (Table 7). These genes include ERCC6, MSH4, PER1, DMC1, and
ERCC5. MSH4 and DMC1 play essential roles in HR during meiosis. (134,135) Because our
focus concerns the repair of DNA damage in mitotic cells, no further investigation on the role
of these genes in AZD2281 sensitivity was performed. PER1 is a clock gene essential for
circadian rhythm. It has been shown to have decreased expression in human cancers
including breast, colon, lung, and endometrial cancer, and decreased expression can reduce
activation of the DNA damage response signal after ionizing radiation. (136) However, these
results have been inconclusive, with subsequent studies unable to validate an effect of PER1
on DNA damage response. (137) Finally, ERCC6 (encoding CSB) and ERCC5 are critical to
DNA damage recognition and repair through the nucleotide excision repair pathway. In the
event of CSB dysregulation, repair cannot proceed through the transcription coupled repair
(TCR) subpathway of NER and must proceed through the slower GGR subpathway.
ERCC5/XPG is an endonuclease in the NER pathway; decreased expression could indicate
a loss of DNA repair through the GGR subpathway of NER. Taken together, the decreased
expression of these two genes could indicate a loss of NER activity in MPNST.
In a previous study to determine mechanisms of sensitivity, aside from HR defects, that
could cause sensitivity to PARP inhibition, C. Lord et al. performed a high throughput siRNA
screen using PARP inhibitor-treated breast cancer cells. (69) They found two novel TCR
genes, XAB2 and DDB1, which sensitized cells to PARP inhibition. Furthermore, they
hypothesized that a defect in the TCR pathway could result in stalled replication forks,
eventual collapse of the replication fork, and highly deleterious dsDNA breaks beyond a
threshold of viability for the cells. Although XAB2 and DDB1 were not specifially differentially
expressed in MPNST cell lines, this study suggests a TCR deficiency as a mechanism of
sensitivity to AZD2281. Furthermore, N. Batenburg et al. recently showed that complete
knockout of CSB decreased the amount of HR and increased the amount of NHEJ compared
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to parental hTERT-retinal pigment epithelial cells. (76) This result also correlated to sensitivity
to Olaparib and decreased damage response signaling after IR. This indicates that CSB plays
a role in facilitating HR repair of DSBs, perhaps by facilitating the recruitment of BRCA1 to
sites of DNA damage, and that loss of CSB drives S/G2 phase NHEJ activity, increasing
genomic instability and subsequently sensitivity to PARP inhibition. However, it is important
to note that this result is shown after complete knockout of CSB, whereas MPNST only shows
decreased expression of CSB. Due to the possible importance of TCR in PARP inhibitor
sensitivity, the observed decrease in HR activity, and because ERCC6 was the most
downregulated DNA repair-related gene found in our MPNST cell panel, we proceeded to
determine its potential important in MPNST sensitivity to PARP inhibition.
CSB is a SWI/SNF-like DNA-dependent ATPase, that along with its role in TCR, has
been reported to play a role in transcriptional elongation at natural transcription pause sites,
resumption of RNA synthesis after DNA damage, as well as chromatin remodeling, and
unwinding of the DNA. (62,138,139) Furthermore, a role for CSB in base excision repair has
been described. (138) Specifically, CSB stimulates either the direct or indirect incision of 7,8dihydro-8-oxoguanine (8-oxoG) residues or alters the DNA structure around the lesion for
better access of other repair proteins during base excision repair. (138,139) CSB interacts
with PARP1 with and without oxidative stress; however, after oxidative stress, these proteins
relocate to sites of DNA damage and CSB becomes PARylated. PARylated CSB has
decreased DNA-dependent ATPase activity, which is not required for its additional activity in
BER, but may affects its ability to change the structure of DNA necessary for TCR. CSB may
also act to keep PARP1 in close proximity to the DNA lesion, aiding in quick repair of the
DNA. Furthermore, it has been shown that in the event of PARP inhibition treatment, CSB
could act in the TCR pathway to repair oxidative DNA damage that remains in the absence
of BER. If CSB were non-functional, single strand breaks could be converted to double strand
breaks at the replication fork. Fittingly, CSB-deficient human fibroblast cells or CSB-null cells
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were shown to be more sensitive to PARP inhibition than those cells complemented with
wildtype CSB or express wildtype CSB. (138,139) This supports a role of CSB in TCR and as
a backup repair mechanism for oxidative DNA damage after PARP inhibition, and shows that
loss of CSB can further sensitize cells to PARP inhibition.
To confirm the downregulation of ERCC6 shown via RNAseq, we first performed qRTPCR of our MPNST cell lines and NSCs. Consistent with the RNAseq results, ERCC6 was
downregulated in MPNST cell lines compared to the NSC control. Confirmation of CSB
expression in a panel of MPNST cell lines and NSCs indicate an average relative CSB
expression 6 times higher in NSC than MPNST cell lines. This corresponds with the
decreased level of CSB expression reported in lung cancer and head and neck squamous
cell carcinoma patients compared to non-cancer controls. (140,141) Decreased CSB
expression, among other deficient NER genes, was also shown to increase the risk of disease
in both models. In addition, the AZD2281 EC50 values for MPNST cells treated for 96 hours
correlate with the observed CSB expression patterns, as assessed by Spearman’s
correlation. Based on this result, we wanted to manipulate the expression of CSB and
determine any effect on the cell sensitivity to AZD2281 treatment.
We anticipate that CSB overexpression would cause the cells to become less sensitive
to drug treatment. Based on the AZD2281 EC50 results, CSB overexpression had an effect
on the AZD2281 sensitivity of S462 and ST88 cell lines but no substantial effect on STS26T
or MPNST724 cells. These results could indicate that STS26T and MPNST724 cell lines have
additional defects in the NER pathway downstream of CSB, beyond the decreased
expression of ERCC5 shown in our RNAseq data, so that while overexpression of CSB has
a mild effect on AZD2281 sensitivity, increase of CSB expression alone is not enough to
overcome other genetic dysregulation. In a previous study by J. Newman et al., re-expression
of wild type CSB in CSB-null, hTERT-immortilized human fibroblasts, caused differential
expression of approximately 150 genes. (139) A subset of the approximately 50 upregulated
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genes after CSB re-expression had a role in DNA repair and drug resistance which could
possibly explain the observed resistance to AZD2281 seen after CSB overexpression in
MPNST. However, M. Caputo et al. report the opposite expression pattern for CSB, with
increased expression of CSB in bladder, cervical, prostate, and breast cancer cell types
compared to normal controls. They hypothesized that CSB plays an anti-apoptotic role in
these cancer cells by re-equilibrating the cell response upon induction of stress, toward cell
proliferation and survival by counteracting p53 activity. (142) Subsequent inhibition of CSB
mRNA expression in these cancer models, reduced cell proliferation and increased the
sensitivity to conventional chemotherapies. ST88 is the only MPNST cell line assessed with
wild-type p53 expression, therefore the increased resistance to AZD2281 observed after
increased CSB expression could be due to increased cell robustness through the interaction
of CSB and p53. In addition, while it is intriguing, we feel the apparent dichotomy of sensitivity
between NF1-associated cell lines and sporadic cell lines to AZD2281 is out of the scope of
this thesis. However, future research should be conducted into how the loss of NF1 in S462
and ST88 cells could contribute to the resistance of these cells to AZD2281 once CSB is
overexpressed.
As a proof of principle, we also knocked down the expression of CSB in MDA-MB-231
cells. This cell line is shown to be relatively resistant to PARP inhibition, therefore we except
if CSB has any role in the sensitivity of cells to AZD2281, that its decreased expression would
cause the cells to become sensitive to treatment. We observed a substantial decrease in the
AZD2281 EC50 of MDA-MB-231 cells with CSB knockdown compared to the control cells.
This indicates that manipulation of CSB alone is enough to induce PARP inhibitor sensitivity
in this cell line. In accordance with these results, we wanted to elucidate if manipulation of
CSB expression would affect the ability of the cells to repair induced UV damage, specifically
CPDs, by the NER pathway, the most defined role for CSB.
To assess the effect of CSB overexpression on MPNST cell response to UV damage,
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we treated the cells with 256J/m2/min UVB and harvested samples 0-24 hours post UV. We
used the treated DNA for an ELISA to measure the amount of resolved CPDs over time. We
expected if CSB overexpression could make the cells less sensitive to PARP inhibition,
potentially by restoring TCR repair of DNA damage, that CSBOE cell lines would be more
proficient in CPD repair than control cell lines. In addition, to confirm that CPDs were resolved
and not converted in double strand DNA breaks, we also performed immunoblots of gammaH2AX, a marker of DNA double strand breaks, at corresponding time points to the ELISA.
Our results show no change in CPD resolution or gamma-H2AX accumulation after UV
damage, regardless of CSB expression level. As previously discussed, CSB has a role in
chromatin remodeling that allows access to the DNA and a role in RNA polymerase II
transcription, potentially supporting transcription as well as DNA repair. (62,138,139)
Therefore, while we expected CSB overexpression or knockdown to effect the efficiency of
repair of CPD damage, the observed effect of CSB expression on AZD2281 sensitivity could
be due to a role of CSB outside of NER. In addition, the MTS assays performed that show a
correlation between CSB expression and AZD2281 sensitivity in a subset of MPNST cell lines
was performed over 7 days; the CPD ELISA was performed over 24 hours. Therefore, the
effect of CSB expression of AZD2281 sensitivity could have a temporal aspect that was not
considered in the CPD ELISA.
Conclusions and Future Directions
MPNST is an aggressive malignancy for which effective targeted therapies are
urgently needed to improve therapeutic options and overall patient survival. In this study,
we demonstrate that PARP inhibition, specifically AZD2281, exerts a strong anti-MPNST
effect in vitro and in vivo as a single agent. This effect could be due to deficient DNA repair
mechanisms, including deficient HR and over-activity of NHEJ, resulting in enhanced
genomic instability, and possibly by decreased expression of CSB. Our study provides
evidence that PARP inhibition, specifically with AZD2281, could hold therapeutic benefit for
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MPNST patients and warrants a clinical trial. However, patients often develop resistance to
single agent treatment, therefore future studies should be aimed at determining a
synergistic drug combination with AZD2281 that could increase efficacy while decreasing
effective doses and off-target effects. Furthermore, additional PARP inhibitors with a similar
mechanism of action as AZD2281 are available, further work to evaluate these drugs for
greater anti-MPNST effects should be done in order to expand potential clinical trial
applications. Importantly, the effect of long term treatment of an inhibitor of DNA repair,
such as AZD2281, should be assessed to determine the potential consequence of
secondary tumorigenesis.
Future investigations are also necessary to determine the specific genetic mutations
or modifications in the HR, NHEJ, and NER pathways that contribute to their dysregulation.
In addition, interrogation of the mechanism of CSB loss could help to expand the potential
patient population that could benefit from PARP inhibition treatment. As previously
mentioned, CSB has multiple roles in the cell beyond DNA repair, including chromatin
remodeling, telomere maintenance, and transcription-associated DNA recombination. (76)
Determining which roles CSB plays in MPNST will be crucial in elucidating the importance
of decreased CSB expression observed in MPNST cell lines. Furthermore, our data
suggests that CSB overexpression in NF1-associated MPNST cells lines has more of an
effect on the resistance to AZD2281 than in the sporadic cell lines. Examination of this
phenomenon could further elucidate the link between CSB expression and PARP inhibitor
sensitivity.
There are several roadblocks to furthering the field of MPNST research including the
limited bioresources available. The creation of human tumor cell lines in order to expand
research data sets would greatly enhance scientific investigation in this field. In addition,
NF1-associated cell lines do not grow in mouse models, severely limiting the amount of
research that can be done in this MPNST subtype. Better mouse models for MPNST, in
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particular NF1-associated MPNST, should be a goal for future research. Furthermore, as
MPNST cell lines do not spontaneously metastasize in mice, metastatic MPNST research
is lacking. Due to the aggressive nature of MPNST and the propensity for these tumors to
metastasize, a mouse model that could better follow the natural order of the disease should
be a priority for future studies and is imperative to more fully understand the biology of this
destructive and lethal malignancy.
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